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Signal transducers and activators of transcription (STAT) are a family of proteins that 
regulate gene transcription. Seven members (STAT1, STAT2, STAT3, STAT4, STAT5a, 
STAT5b, STAT6) have been identified in human STAT family since two decades ago. 
As a member of the STAT family, STAT5 plays a central role in transmitting signals 
from transmembrane receptors such as cytokine receptors and growth factor receptors 
to the nucleus. It has been found that STAT5 is constitutively phosphorylated at a 
conserved tyrosine residue located at the end of SH2 domain by various activated 
tyrosine kinases in a broad range of human cancer cells. Inhibiting STAT5 has been 
considered as a promising approach for cancer therapy. However, STATs have been 
described as difficult pharmacological targets and small-molecule inhibitors of STAT5 
are poorly investigated. 
The subject of this work is the investigation of small-molecule inhibitors 
targeting STAT5b-SH2. The tetrazole-containing active compounds discovered in this 
work are derived from the furazan-based phosphate mimetics. In the first section of 
this work, a structurally stable scaffold was designed. The aim is to improve the 
binding affinity of the existing inhibitors and to avoid the instability. For this purpose, 
four different methods were tried to synthesize the new structures. The main problem, 
low reactivity of the amino group in fragment 1 in the formation of a linkage between 
the furazan ring and the 5-position in the tetrazole ring, was solved in the 
N-cyanomethyl amine synthetic method. The obtained compounds showed expected 
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stability under acidic conditions. However, these compounds were surprisingly 
inactive in a FP binding assay.  
In the second section of this work, a series of 1-aminomethyl tetrazoles based on 
the structures with different substituents at the 5-position of the tetrazole ring was 
synthesized via Mannich ligation reaction. Most of them displayed binding affinity to 
STAT5b-SH2 in low micromolar range in the FP-based competitive binding assay, in 
which compound 24 was the most active one with a Ki value of 1.8 µM. To 
investigate how different substituents at the 5-position of the tetrazole ring influence 
the stability of the scaffold, a systematic stability analysis was carried out on LC-MS 
and compounds 19, 22, 24, and 25 were found to possess better stability in contrast 
with the lead compounds 2 and 3. Furthermore, the binding of compound 24 to 
STAT5b-SH2 and the pivotal role of Asn642 were proven in the binding assays. 
Finally, the inhibitory activity of compounds 3 and 24 on leukemic cell proliferation 
was determined by the Alamar Blue assay. 
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1.  Introduction 
1.1. STAT5 protein 
Signal transducers and activators of transcription (STAT) are a family of proteins that regulate 
gene transcription. They were first identified over two decades ago as transcription factors in 
the context of interferon signaling1-3. There are seven members (STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b, STAT6) in the human STAT family that have been identified. In 
cytoplasm these proteins play a role as cytosolic signaling proteins while in the nucleus they 
mediate expression of genes regarding proliferation, apoptosis, differentiation and 
inflammation4-6. STAT proteins have essential roles in a variety of human cells, particularly in 
immune and blood cells7-9. 
As a member of the STAT family, STAT5 is involved in a broad range of human cancers 
and has been considered as a high value target for cancer therapy10-14. It is expressed in two 
forms of STAT5a and STAT5b, showing around 94% sequence identity at the amino acid 
level15. STAT5a and STAT5b are often referred to collectively as STAT5. Apart from the 
N-terminal domain and the C-terminal transactivation domain, the core fragment of STAT5 
structure comprises of four parts (Figure 1.1): a coiled-coil domain, a DNA binding domain, a 
linker domain and an SRC-homology type 2 (SH2) domain16, 17. The coiled-coil domain is 
involved in various early events in STAT5 activation and function, the DNA binding domain 
regulates recognition of specific DNA sequences for binding, the linker domain is responsible 
for keeping the appropriate structure for DNA binding as well as nuclear export, and the SH2 
domain plays a critical role in STAT5 activation and dimerization through its phosphotyrosine 
recognition area to regulate gene transcription. Besides, a conserved tyrosine residue (residue 
694 and 699 for STAT5a and STAT5b, respectively18), which is crucial for STAT5 





Figure 1.1. The structure of STAT5 protein, in which the SH2 domain (in yellow) plays a critical role in 
STAT5 activation and dimerization19. 
The crystal structure of unphosphorylated mouse STAT5a core fragment (PDB: 1Y1U)20, 
lacking both the N-terminal and the C-terminal transactivation domains was published in 
2005, which has allowed for a number of computational studies of STAT5 to be performed in 
the past years21-25, leading to a better understanding of the protein structure and relevant 
molecular mechanisms. Most recently, the core fragment of unphosphorylated human STAT5b 
was crystallized (PDB 6MBW) and the structure was solved via molecular replacement with 
mouse STAT5a26. 
1.2. STAT5 signaling 
STAT5 plays a central role in transmitting signals from transmembrane receptors such as 
cytokine receptors4, 27, 28 and growth factor receptors29, 30 to the nucleus (Figure 1.2). It is 
responsible for activation of genes that are involved in essential cellular functions10, 31. In 
normal cells, the signaling cascade begins at the cell surface. When ligands bind to the 
extracellular pockets of the upstream receptors, kinases are activated to phosphorylate specific 
tyrosine residues on the receptor’s cytoplasmic domains. STAT5 proteins are recruited to bind 
to the phosphotyrosine residues of these receptors via SH2 domain. There, each of the bound 
STAT5 proteins is phosphorylated by tyrosine kinases such as JAK232-34 at the conserved 
tyrosine residue 694/69918 and then released from the receptors. The subsequent 




cytoplasm generates phospho-STAT5 dimers35. The phosphorylated dimers are able to 
translocate into the nucleus where they bind to target DNA sequences to regulate gene 
transcription and expression, although they are rapidly deactivated by a number of 
intracellular mechanisms, including cytosolic and nuclear phosphatase19, 36. 
 
Figure 1.2. STAT5 signaling induced by activated transmembrane receptors and cytoplasmic tyrosine 
kinases. 
In cancer cells, however, STAT5 is constitutively phosphorylated by activated upstream 
kinases37-39 even without ligand-induced receptor stimulation due to numerous reasons such 
as receptor mutations40-42 and altered expression and activity of cytoplasmic tyrosine kinases32, 
43, 44, leading to elevated expression levels of the target genes including Pim1 with 
pro-proliferative function, Bcl-xl with anti-apoptotic function, and Cis with negative 
regulatory function45-47. Constitutive phosphorylation of STAT5 has been proved to be a 
crucial role in various cancer types including acute myeloid leukemia, chronic myeloid 




upstream STAT5 inducers to block STAT5 signaling have been reported49-54. However, the 
upstream tyrosine kinases usually are involved in many other downstream pathways except 
for STAT5 signaling. As a result, indirect strategies inhibiting STAT5 signaling could also 
generate strong undesirable effects. For example, it is common for cancer cells to develop 
resistance to tyrosine kinase inhibitors that specifically target FLT355, 56, which is a 
constitutively active tyrosine kinase that drives the pathogenesis of acute myeloid leukemia. 
On the other hand, it is unrealistic to inhibit all the upstream STAT5 inducers at one time57 or 
with a single inhibitor. Thus, investigating inhibitors that are capable to directly block STAT5 
phosphorylation and dimerization is of great meaning for anti-cancer drug discovery. 
1.3. Phosphate mimetics 
As mentioned before, inactive STAT5 monomers becomes capable of triggering downstream 
signaling pathways when they are phosphorylated at the conserved tyrosine residues by 
kinases after binding to phosphotyrosine-containing receptors via phosphoryrosine 
recognition area in SH2 domain. Afterwards, posphorylated STAT5 monomers dissociate 
from the receptors to form dimers by mutual binding of individual phosphorylated tyrosine 
sequences to the binding pockets within paired SH2 domains. In consequence, the SH2 
domain serves as the binding target of phosphotyrosine residues of upstream receptors as well 
as those of phosphorylated STAT5 monomers. To inhibit the aberrant activation and 
transcriptional influences of STAT5 proteins in cancer cells, phosphate mimetics that occupy 
the phosphotyrosine recognition area24, 35 in the SH2 domain to block phosphorylation and 
dimerization of STAT5 proteins could be potential anti-cancer drugs. Indeed, highly potent 
peptide-based phosphotyrosine mimetics has been reported58, 59, although they usually fail to 
exhibit significant cellular activity. Meanwhile, active small-molecule inhibitors directly 
targeting on the phosphotyrosine binding pocket have been discovered successively in recent 





1.4. 4-Amino-furazan-3-carboxylic acid 
In the previous work of Wong and coworkers65, a fluorescence polarization (FP) screening 
utilizing a fragment library to discover phosphate mimetics was performed. The protein used 
in the FP assay was a recombinant MBP-fusion STAT5b-SH2 domain. One active fragment, a 
furazan derivative 1 with a KD value of 420 µM and high ligand efficiency66 of 2.1 kJ mol-1 
per non-hydrogen atom was selected as a promising phosphate mimetic for further 
optimization. In a thermal shift assay the melting point of STAT5 protein was increased by 
3 °C after treatment of 1, implying binding events existed between 1 and STAT5. Molecular 
docking of 1 into homology model of human STAT5-SH2 phosphotyrosine binding site 
indicated that the binding mode consisted of interaction between the carboxylate anion and 
the protonated Arg618 and several hydrogen bonds involving Arg618, Ser622 and Asn642. 
Interestingly, N642H was found to be a driver mutation for T-cell leukemia26, 67-69. 
 
Figure 1.3. Molecular docking of phosphate mimetic 1 into the homology model of human STAT5-SH2 
phosphotyrosine binding pocket (generated from the published structure of STAT5a, PDB 1Y1U). Arg618, 




1.5. Protein-induced fragment ligation products 
Protein-induced fragment ligation has been described as a powerful method for protein 
ligands discovery70-72. This method based on the theory that a protein has the potential to 
serve as a binding template to catalyze specific multi-component reactions to form more 
active ligands by linking less active fragments together. The fragments usually have low 
binding affinities respectively to several adjacent binding pockets in the protein. The range of 
applicable reaction types has been expended in recent years73-77. In order to expand the 
structure of phosphate mimetic 1 and increase the possibility of discovering more active 
molecules, protein-induced fragment ligation methods were carried out by Wong65. At first, 
amidation of the amino group with different acyl chlorides, which is an effective method in 
fragment-based drug discovery78 was introduced, resulting in several amide derivatives. None 
of them, however, were active in the FP assay. One possible reason was that the carbonyl 
linker couldn’t make the molecule flexible enough to fit the phosphotyrosine binding pocket 
in the STAT5-SH2 domain. Thus, an alternative featured with Mannich ligation reactions was 
investigated. Fragment 1 was able to react with formaldehyde and some N-containing 
heteroaryl nucleophiles at room temperature to give 1-aminomethyl tetrazole products. The 
three-component Mannich ligations generated the products in acidic condition, whereas no 
product was observed at pH 7.4. Taking the above findings and the theory of protein-induced 
fragment ligation into account, a reasonable assumption was that if STAT5 protein could 
catalyze a Mannich ligation reaction to happen at pH 7.4, then the corresponding product 
would very likely to be a ligand to STAT5. The assumption was verified in the following 
investigations involving thermal shift assay (TSA), FP assay and HPLC-QTOF-MS analysis, 
in which 1H-tetrazole was used as an N-containing heteroaryl nucleophile. To exclude the 
interferences from any other primary and secondary amines in the Mannich ligation, a MOPS 
buffer at pH 7.4 was used in the assays. In the TSA, an obvious shift of the MBP-STAT5-SH2 
protein’s melting point was recorded after incubation of 1, formaldehyde and 1H- tetrazole at 




tetrazole were incubated in a similar way at pH 7.4, the FP values decreased with the increase 
of formaldehyde concentration. These two binding assays suggested the protein-induced 
formation of an inhibitor. Furthermore, the product formation was detected and quantified by 
HPLC-QTOF-MS analysis. As anticipated, incubation with protein led to the formation of 2, 
while incubation without protein didn’t show any product formation. However, when the 
same assay was carried out at pH 5.0, the product was formed no matter there’s protein in 
presence or not. Similar results were obtained when 1H-tetrazole was replaced by 
5-benzyl-1H-tetrazole in the assay. And replacement of MBP-STAT5-SH2 protein by MBP 
and other proteins didn’t induce the ligation in the same conditions. Both ligation products 2 
and 3 were re-synthesized, purified and tested in the FP assay, showing low-micromolar 
affinities to STAT5-SH2 protein, which was a significant improvement compared with that of 
fragment 1.  
          
Figure 1.4. Derivatives 2 and 3 of lead compound 1 showed improved binding activity to STAT5-SH2. 
The predicted binding mode of 2 to STAT5-SH2 indicated that the original interactions 
were retained and the expansion of structure introduced additional hydrophobic interactions to 
the adjacent pocket involving Trp641, Leu643, and Met639 residues. What’s more, hydrogen 
bonds between the tetrazole ring and the amide-NH2 of Asn642 could strengthen the binding. 
The crucial role of Asn642 in the increased affinity was further confirmed by a ligation assay 
with structurally related Asn642-lack GST-STAT3 protein. No Mannich ligation reaction was 





Figure 1.5. Predicted binding mode of compound 2 to the homology model of human STAT5-SH2. 
Additional hydrogen bonds between the tetrazole ring and Asn642 were suggested65. 
To investigate the specificity of these STAT5 inhibitors from Mannich ligation, various 
assays were performed. The ligation product 2 showed inhibition or binding specificity to 
STAT5 in comparison with SHP2 in enzyme assays and STAT3 in FP assay. Besides, 2 
inhibited STAT5-DNA complex formation while the corresponding DNA complex formation 
of STAT1 and STAT3 were not suppressed. The inhibitors were further studied in living cells 
and animals. In BaF3 cells carrying FLT3-ITD mutation79, a common AML model, STAT5 is 
constitutively phosphorylated. The cells were treated with re-synthesized Mannich ligation 
products and STAT5 phosphorylation level was determined using phosphotyrosine-specific 
antibodies afterwards. The results indicated 3 and the methyl ester derivative of 2 reduced 
STAT5 phosphorylation in BaF3 cells with FLT3-ITD mutation. What’s more, transcription 
and protein expression of three important target genes of STAT5, Pim1 kinase, Bcl-xl and Cis, 
were also found significantly suppressed by analyzing mRNA in qRT-PCR study. In MV-4-11 
leukemic cells inhibitor 3 showed synergistic effects with FLT3-inhibitor PKC412 in 
inhibition of reporter gene expression, STAT5 phosphorylation and cell proliferation. In a 
murine model of leukemia, tumor growth in nude mice with inoculated BaF3/FLT3-ITD cells 
after treatment with 3 was delayed compared with the control group. 
All these findings suggest that the products of Mannich ligation reactions of fragment 1, 




promising anti-tumor efficacy. The furazan-based phosphate mimetics paved the way for 







2.  Objectives and planning 
STAT proteins have been described as difficult pharmacological targets9, 80, 81. While many 
indirect inhibitors of other STAT family members are currently found at different stages of the 
pharmaceutical drug discovery process49, 82, 83, the development of novel cancer therapeutics 
against STAT5 has been poorly investigated. To date only a few examples of chemical entities 
that specifically target this oncological protein have been published84, 85. In Wong’s work, 
fragment 1 was proven as a phosphate mimetic to be able to form critical interactions with 
STAT5 SH2 in the phosphotyrosine binding area. With the help of a protein-templated drug 
discovery method utilizing Mannich ligation reactions65, the tetrazole moiety was attached to 
fragment 1, affording several active ligation products (1-aminomethyl tetrazoles) with STAT5 
inhibitory activity. In the binding assays, the activity of these 1-aminomethyl tetrazoles was 
demonstrated to be significantly improved if compared with that of fragment 1. However 
these compounds only showed limited activity in cellular assays. Besides, they were found 
not stable in aqueous solutions especially in acidic condition. For example, inhibitor 3 was 
decomposed in acidic mobile phase when analyzed by LC-MS. But the decomposition degree 
of these compounds could be very different due to different types of the substituents at the 
5-position of the tetrazole ring. The instability of the existing 1-aminomethyl tetrazoles could 
have a negative impact on the results of further biological evaluations since fragment 1 only 
showed a binding activity of 420 µM to STAT5 protein and 5-substituted tetrazoles alone 
were not active towards the target protein. Furthermore, no inhibitor-protein complex was 
found in the protein mass experiment excluding an irreversible binding mode. If the 
compounds get decomposed easily, their inhibitory effect on STAT5 would very likely be 
weakened. Thus, the first aim of this work is to discover STAT5 inhibitors with improved 
stability and potency based on the existing structure. The second aim is to further understand 
the role of the tetrazole moiety in the binding to STAT5-SH2. The third aim is to clarify how 
2. Objectives and planning 
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the acidity and the substituents on the tetrazole influence the scaffold’s stability. To achieve 
these goals, structural modifications on the existing compounds were planned as follows. 
To modify the structure of the 1-aminomethyl tetrazoles, one option is to change the 
scaffold itself. But the change should not be too extensive, so as not to generate unfavorable 
effects on the activity towards STAT5 protein. The plan is to exchange the positions of the two 
substituents on the tetrazole ring leading to the scaffold of 5-aminomethyl tetrazole, in which 
the connection between the furazan ring and the tetrazole ring should be more stable. And by 
comparing the activity of 5-aminomethyl tetrazoles with that of 1-aminomethyl tetrazoles, the 
ligand-protein interactions can be further understood. Another way of structural modification 
is to attach different substituents to the 5-position of the tetrazole ring. Because structure 
expansion could bring the possibility of binding to additional sites that were beyond reach 
previously. Besides, different substituents at the tetrazole ring could have diverse impacts on 














3.  Limitations of the existing compouds 
In the previous work done by Wong65, a number of fragment 1 based compounds were 
synthesized and tested. For example, amidation on the amino group of compound 1 with 
various acyl chlorides furnished N-acetyl derivatives. However, none of the amides were 
active in the binding assay probably because of the steric effect of the carbonyl linkage on 
ligand-protein interactions. 
 
Figure 3.1. Examples of amidation products of fragment 1. 
In the Mannich ligation expansion of compound 1, different N-heterocycles were used 
with formaldehyde to give various ligation products. It was discovered that products with 
five-membered N-heterocycles generally displayed enhanced inhibitory activity towards 
STAT5. For example, the compounds with 1,2,3-triazole ring (B1 and B2) showed an increase 
of affinity in around 2 fold while the 1,2,4-triazole compound B3 in over 9 fold. The pyrazole 
containing compound B4 also showed an over 3 fold enhancement of binding affinity to 
STAT5. The most significant improvement of activity was found in the derivatives with 
5-substituted tetrazoles (e.g. compounds 2 and 3, mentioned in the introduction chapter), in 
which some of the them (C3 and C4) even possessed submicromolar activity. 




Figure 3.2. Examples of the active compounds derived from Mannich ligation reactions (with Ki values in 
the FP assay from Wong’s work65). 
Despite the improved activity of the tetrazole-containing ligation products showed in 
binding assays, several problems regarding the properties of the structures limited the further 
investigations. In cellular assays, compounds C1, C3 and C4 precipitated in buffer, resulting 
in failed tests. Other compounds that were soluble in DMSO and buffer, however, showed 
limited cellular activity. For example, compound 2 inhibited the phosphorylation of STAT5 in 
leukemic cells with an IC50 of only over 100 µM. The instability of these compounds could be 
a reason for the low cellular activity. The 1-aminomethyl tetrazoles were found to be 
decomposed into fragment 1 and corresponding 5-substituted tetrazoles in the process of 
chromatography (Figure 3.3), which will be discussed in detail in the following chapters.  




Figure 3.3. Compound 3 was decomposed in the process of chromatography using acidic mobile phase 
(wavelength = 254 nm). 
Given the above limitations, optimization of the 1-aminomethyl tetrazoles is needed to 







4.  Study of 5-aminomethyl tetrazoles 
4.1. Synthesis of 5-aminomethyl tetrazoles 
The instability of 1-aminomethyl tetrazoles has a negative impact on subsequent activity 
studies. To overcome this problem, a modification on the structure is needed. The purpose of 
the modification is not only to find a stable scaffold but also to keep the existing activity. Thus, 
exchanging of the two substituents on the tetrazole ring, which leads to 5-aminomethyl 
tetrazoles, seems to be a reasonable way since the minimum extent to which the original 
structure to be changed. The key binding interactions between the ligand and the protein, 
involving residues such as Arg618, Ser622 and Asn642 were expected to be retained. In order 
to obtain the 5-aminomethyl tetrazole scaffold, different synthetic routes were designed and 
carried out (Scheme 4.1). 
 
Figure 4.1. Structure modification from 1-aminomethyl tetrazole to 5-aminomethyl tetrazole. 




Scheme 4.1. Retrosynthetic analysis of 5-aminomethyl tetrazole compounds. 
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4.1.1. Reductive amination method 
To synthesize the 5-aminomethyl tetrazole structure, a 4-step synthetic route starting from 
2,2-diethoxyacetonitrile was designed (Scheme 4.2). In the conversion of 
2,2-diethoxyacetonitrile to 5-(diethoxymethyl)-1H-tetrazole (31), sodium azide or trialkyltin 
azides86-88 were first used as the azide source and the reaction mixture was stirred and heated 
under microwave irradiation. However, the yields were too low to proceed the following 
reaction. In the attempt to increase the yield, the azide source was changed to hydrazoic acid 
according to Pireto’ work89. The hydrazoic acid solution was prepared in advance by addition 
of sulfuric acid into a suspension of sodium azide in chloroform under cooling. By use of 
hydrazoic acid solution, the yield was increased to 57%. Subsequent substitution of 
compound 31 at tetrazole’s 1-position with a benzyl group was straightforward. The following 
hydrolysis to give the corresponding aldehyde compound 34 was achieved by use of 
hydrochloric acid.  
 
Scheme 4.2. Reductive amination method for the synthesis of compound 46. Reagents and conditions: (a) 
4. Study of 5-aminomethyl tetrazoles 
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HN3, pyridine, CHCl3, RT, O/N, 57%; (b) PhCH2Br, Cs2CO3, DMF, 100 °C, O/N, 67%; (c) HCl, H2O, 
50 °C, 2.5 h, 90%. 
The final step was a reductive amination reaction involving either 
4-amino-furazan-3-carboxylic acid 1 or the methyl ester compound and 34. The amine and the 
aldehyde were first dissolved in methanol and stirred at room temperature. After 2 h, the 
mixture was treated with reducing agents such as sodium borohydride (NaBH4), sodium 
cyanoborohydride (NaBH3CN) and sodium triacetoxyborohydride (NaBH(OAc)3). However, 
no product was found in either case. Various attempts including changing of different solvents 
(e.g., EtOH, i-PrOH, THF, DCM, MeCN, DMF), removal of water and increasing the reaction 
temperature were made but none of them was able to solve the problem. Actually, there was 
no obvious imine intermediate detected in the reaction process even sufficient time was given 
before introducing a reducing agent. The reason could be attributed to the low reactivity of the 
primary amino group of compound 1. The strong electron-withdrawing effect of the furazan 
ring dramatically disperses the negative charge on the N atom of the amino group. As a result, 
the amine addition on the aldehyde carbonyl is difficult to proceed, which is the first step of 
the mechanism of reductive amination (Scheme 4.3). Consequently, there won’t be enough 
imine or iminium ion to be reduced into the expected product in the following step. 
 
Scheme 4.3. Theoretical mechanism of imine formation in reductive amination. 
4.1.2. N-Benzyl-2-chloroacetamide method 
N-Benzyl-2-chloroacetamide is able to be transformed into 1-benzyl-5-(chloromethyl)- 
1H-tetrazole in a one-pot reaction involving chlorinating reagent phosphorus pentachloride 
(PCl5) and azide source hydrazoic acid (HN3) in toluene90, 91. In this tetrazole formation 
4. Study of 5-aminomethyl tetrazoles 
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process, the addition of PCl5 on the carbonyl of N-benzyl-2-chloroacetamide happens at first. 
After cleavage of a POCl3 and a chloride ion, the chloroimine intermediate forms. The 
subsequent conversion into the tetrazole compound after the attack of azide anion on the 
imine carbon is straightforward (Scheme 4.4). Thus, a synthetic route to furnish 
5-aminomethyl tetrazoles was designed including a tetrazole formation step and an amine 
alkylation step. In theory, the order of these two steps could be interchanged (Scheme 4.6). 
DMF was used as solvent in the SN2 alkylation reaction and different bases such as K2CO3, 
NaHCO3, Cs2CO3, Et3N were tried as additives in order to eliminate acid. However, the 
alkylation of the amino group in compound 1 was not successful in either route. The reason is 
that the 4-amino-furazan compound is a weak nucleophile under the influence of the furazan 
ring, and the chloride compounds are not active enough to promote the nucleophilic attack 
from the amine. So potassium iodide, a commonly used activating agent92, 93, was added into 
the reaction leading to in situ formation of the corresponding iodide from the chloride 
compound (Scheme 4.5). Unfortunately, no product was found in the following nucleophilic 
substitution reaction either. The low reactivity of the 4-amino-furazan compound is still a key 
problem in this method. 
 
Scheme 4.4. Synthetic mechanism of compound 36 from N-benzyl-2-chloroacetamide using phosphorus 
pentachloride and hydrazoic acid. 




Scheme 4.5. Chlorides can be activated to corresponding iodides to undergo nucleophilic substitution from 





Scheme 4.6. N-benzyl-2-chloroacetamide methods for the synthesis of compound 46. Reagents and 
conditions: (a) PCl5, HN3, toluene, 80 °C, O/N, 92%. 
4.1.3. Sandmeyer reaction method 
As previously mentioned, the amino group of 4-amino-furazan reactant was not active enough 
to react with 34. Thus, an alternative way using (1-benzyl-1H-tetrazol-5-yl)methanamine (39) 
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as a nucleophile was designed (Scheme 4.7). N-benzyl-2-(1,3-dioxoisoindolin-2-yl)acetamide 
(37) was first synthesized from 2-(1,3-dioxoisoindolin-2-yl)acetic acid in a one-pot amidation 
reaction. The next step was tetrazole formation, in which hydrazoic acid and phosphorus 
pentachloride were used (the mechanism has been discussed in the previous method). Primary 
amine 39 was then released from the phthalimide compound 38 by reaction with hydrazine 
(Scheme 4.8). On the other hand, the amino group of 4-amino-furazan compound should be 
halogenated as a electrophile to react with compound 39. To achieve this goal, Sandmeyer 
reaction was employed94, 95. Both sodium nitrite and tert-butyl nitrite were tried to form 
nitrosonium ion in acidic condition (Scheme 4.9-1), which theoretically acts as an 
electrophile to react with the heterocyclic amine to form corresponding diazonium salt 
(Scheme 4.9-2). The diazonium ion then reacts with CuBr through a radical mechanism to 
lose a nitrogen molecule, forming the brominated product (Scheme 4.9-3). However, no 
product formation was found under the above conditions when using the methyl ester of 
compound 1. In this case, the nucleophilic attack of the amine on the nitrosonium ion 
probably didn’t happen readily because of the low electron density on the nitrogen atom of the 
amino group. 
 
Scheme 4.7. Sandmeyer reaction method for the synthesis of compound 46. Reagents and conditions: (a) (i) 
(COCl)2, DMF, DCM, RT, 4h, (ii) BnNH2, Et3N, RT, 30 min. 98%; (b) PCl5, HN3, toluene, 80 °C, O/N, 
78%; (c) N2H4, EtOH, reflux, 1.5 h, 85%. 











Scheme 4.9. Mechanism of Sandmeyer reaction to synthesize an aryl bromides from an aromatic amine. 
Formations of nitrosonium ion (4.9-1), diazonium ion (4.9-2), and aryl bromide (4.9-3). 
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4.1.4. N-Cyanomethyl amine method 
According to the previous reactions involving 4-amino-furazan compounds, formaldehyde 
seems to be a rare electrophile that is able to react with the amino group on the furazan ring. 
And considering the structure of 5-aminomethyl tetrazoles, a Strecker-type96 nitrile 
intermediate (40) derived from 4-amino-furazan-3-carboxylic acid could be an alternative for 
tetrazole formation (Scheme 4.10). The synthesis of compound 40 involves imine formation 
and subsequent nucleophilic attack from a cyanide anion. At first, trimethylsilyl cyanide was 
used96-98 in the reaction but no product was found. The categories of solvent used in this 
reaction were very limited. After a series of trials, DMSO was found to be the only feasible 
solvent to make the reaction happen. The reaction condition was mild and the workup went 
through column chromatography to obtain the nitrile compound 40 as a white solid. For the 
subsequent tetrazole formation reaction, the commonly used microwave-assisted reaction 
resulted in a very low yield. After study of related literatures and several trials, a method 
based on Sharpless’ work99-102 was applied. The nitrile compound was treated with sodium 
azide and catalyst zinc bromide in a mixture of water and isopropanol at room temperature to 
give corresponding tetrazole compound effectively. A possible mechanism is that, zinc cations 
play a coordination role by forming complex structures with nitrile nitrogen. This 
coordination increases the polarization of the nitrile moiety and lowers the energy barrier for 
nucleophilic attack by azide anion. The N-cyanomethyl amine compound 40 is able to react 
with sodium azide to produce the corresponding tetrazole compound 41. Based on compound 
41, the following esterification, substitution and hydrolysis were carried out to give 
5-aminomethyl tetrazoles (45 and 46) successfully.  




Scheme 4.10. Cyanomethyl amine method for the synthesis of compounds 45 and 46. Reagents and 
conditions: (a) HCHO, KCN, DMSO, RT, 4 h, 67%; (b) NaN3, ZnBr2, H2O/iPrOH, 80 °C, 7 h, 84%; (c) 
MeOH, reflux, 20 h, 91%; (d) PhCH2Br, Et3N, MeCN, RT, 24 h, 24% (43) and 21% (44); (e) NaOH, 
MeOH/H2O, 1.5 h, 79%; (f) NaOH, MeOH/H2O, 1 h, 76%. 
Notably, in the substitution reaction a mixture of 1,5- and 2,5-disubstituted tetrazoles (43 
and 44) were found as products with close yields. One possible reason of the isomeric 
products formation is that an unstable bimolecular intermediate generates in the process103-106. 
The negative charge of the tetrazolate ion is dispersed among the four nitrogen atoms, 
offering two different sites for the substitution to proceed (Scheme 4.11). 
 
Scheme 4.11. Mechanism of the formation of 1,5- and 2,5-disubstituted tetrazole isomers in the reaction 
between a tetrazolate anion and an alkyl bromide. 
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4.2. Stability study of 5-aminomethyl tetrazoles 
Stability study of compounds 45 and 46 was carried out on LC-MS (Figure 4.2). The 
compounds were first dissolved in 10 mM ammonium acetate buffers with pH values 1, 3, 5 
and 7. After 30 min the solutions were analyzed by LC-MS at 254 nm wavelength with a 10 
mM ammonium acetate mobile phase at physiological pH. As anticipated, all the eight 
chromatograms showed only one peak respectively. This means no decomposition has 
happened and the two molecules are stable in acidic conditions. 
    (a)                                       (b) 
     
Figure 4.2. Stability of compounds 45 (a) and 46 (b) detected by LC-MS (DAD 254 nm). The two 
molecules are stable in acidic conditions. 
4.3. FP assays with STAT5b-SH2 
To determine the activity of the stable 5-aminomethyl tetrazoles, a competitive fluorescence 
polarization (FP) assay was applied107-109 (Figure 4.3). In this assay, a potent probe is excited 
by linearly polarized light and rotate rapidly, resulting in a low spatial orientation when 
fluorescence emission happens. It is recorded as a low degree of fluorescence polarization. 
Upon binding to the target protein the rotation of the probe is slowed down because of the 
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significantly increased molecular weight. Thus, the orientation becomes more uniform and the 
degree of fluorescence polarization is increased. If a small molecule possessing binding 
affinity to the protein is added to replace the probe from the binding pockets, a decrease of 
fluorescence polarization can be detected because the molecular weight is reduced and the 
rotation of the probe is speeded up again.  
 
Figure 4.3. The mechanism of fluorescence polarization assay. 
To conduct the competitive FP assay, the dissociation constant (KD) between the protein 
and the probe is needed, on which the protein concentration used in the following experiments 
are dependent. The protein used in this work was a recombinantly expressed STAT5b-SH2 
fused to maltose-binding protein (MBP) as affinity tag. A highly potent fluorophore-labeled 
peptide 5-CF-GpYLSLPPW-NH2 was synthesized as the probe. Hence, a binding assay was 
first performed by treating 10 nM of the fluorophore-labeled peptide with varying 
concentrations of MBP-STAT5-SH2. The KD value was determined by the protein 
concentration when 50% of the probe molecules were bound.  




Figure 4.4. Binding of peptide 5-CF-GpYLSLPPW-NH2 to MBP-STAT5b-SH2. (error bars denote mean ± 
SD, n = 2). 
Then the competitive FP assays were conducted to test the known active compounds 2 
and 3 (Figure 4.5), which are isomers of the synthesized 5-aminomethyl tetrazoles. Serial 
concentration of the compounds were added into the buffer to compete with the potent probe 
for the binding to STAT5 protein. By measuring the fluorescence at different concentrations of 
the compounds, the IC50 values were determined.  
Nevertheless, it is sometimes difficult to compare the IC50 values measured under 
different experimental conditions and from different research groups110. A common practice is 
to convert them into inhibition constants (Ki), which is theoretically only dependent on the 
temperature. The conversion can be achieved by applying the Cheng–Prusoff equation111, 112 





Equation 4.1. Cheng-Prusoff equation for the calculation of the Ki values in receptor-ligand binding 
assays111, 112. 
In a competitive binding assay, the concentration of the free probe usually cannot be 
measured directly. Accordingly, one solution is using the total concentration of the probe 
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instead of the free one. In the FP-based competitive binding assay, however, the experimental 
conditions are formulated to maximize the range of the mP shift. The concentration of the 
probe is lower than the KD value and the concentration of the protein is higher than the KD 
value (twice of the KD value in this work) so that the polarization value before adding an 
inhibitor is close to the maximal mP. Since the majority of the probe is bound to the protein, 
the approximation of the free probe concentration to the total concentration must introduce a 
significant error. Besides, it was demonstrated that higher concentrations of the protein 
resulted in higher IC50 values for the same inhibitor in the competitive FP assays. Thus, all the 
IC50 values of the compounds in this work were converted to Ki values using a modified 
Cheng-Prusoff equation113 (Equation 4.2) with a correction factor for the protein 
concentration, which is more precise than the original equation. Compound 2 and 3 showed Ki 















Figure 4.5. Competitive FP assay results of compounds 2 (a) and 3 (b), showing Ki values of 2.2 µM and 
3.8 µM respectively (error bars denote mean ± SD, n = 2). 
The stable 5-aminomethyl tetrazoles were also tested following the same protocol 
(Figure 4.6).  First, compound 41 was measured in serial concentration ranging from 0.5 
mM to 30 nM, however, it was inactive. While its 5-aminomethyl tetrazole isomer 2 
possessed a Ki value of 2.2 µM (1.4 µM in Wong’s work65). Next, compound 45 and 
compound 46 were tested in the same condition. The results showed that neither of them were 
active. In comparison, the isomer 3 had a Ki value of 3.8 µM (2.9 µM in Wong’s work65). 
(a) 
 







Figure 4.6. Competitive FP assays suggested 5-aminomethyl tetrazole compounds 41 (a), 45 (b), and 46 (c) 
were inactive to MBP-STAT5b-SH2 (error bars denote mean ± SD, n = 2). 
The unexpected results imply that some critical interactions between the inhibitor and 
STAT5 must be lost after the scaffold 1-aminomethyl tetrazole was transformed to 
5-aminomethyl tetrazole. More specifically, the conversion of C-N bond to C-C bond between 
the aminomethyl group and the tetrazole ring results in the loss of binding activity to STAT5. 
According to the binding mode of 1-aminomethyl tetrazole to STAT5-SH2, Asn642 is a key 
residue in the neighboring area of the C-N bond within the phosphotyrosine binding site. The 
amide amino of Asn642 serves as hydrogen bond donor to attract the tetrazole ring to the 
pocket. The adjacent residues Trp641, Leu643, and Met639 make up an amphiphilic pocket 
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that can also form interactions with the tetrazole moiety. Compound 1 is not capable of 
forming these interactions with STAT5, which leads to a significant difference in binding 
affinity in contrast to the tetrazole-containing derivatives. This is a hint to explain the 
completely different affinities between 2 and 41, 3 and 46, although they are structurally 
similar. As the conversion of C-N bond to C-C bond could alter the tetrazole’s energetically 
favorable pose, keeping the moiety away from Asn642 and the adjacent pocket, leading to its 
exposure to the solvent. Besides, the conformation change could in turn break the adjacent 
hydrogen bond between the secondary amino group and Asn642, resulting in a potential 
binding mode that is similar to that of the phosphotyrosine mimetic 4-formylphenyl phosphate 
reported in Wong’s work65 (Figure 4.7). Considering the phosphotyrosine binding site is a 
shallow pocket, it seems unlikely for the new conformation to generate extra interactions 
within this area. 
 
Figure 4.7. Molecular binding mode of phosphotyrosine mimetic 4-formylphenyl phosphate to STAT5 
phosphotyrosine binding site. Hydrogen bonds are shown as red dashed lines65. 
Another possible reason for the activity difference was predicted in a new molecular 
docking experiment by using the homology model of human STAT5b-SH2. Five possible 
active sites of the SH2 domain were calculated by the software Molecular Operating 
Environment (MOE). One site that includes Lys600, Arg618, Asp621, Ser622, Asn642, and 
Met644 best matches the phosphotyrosine binding area was chosen as the docking pocket. 
Compounds 2 and 41 were then docked into the pocket respectively and 10 poses for each 
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compound were generated by GOLD. The preferred binding mode of active compound 2 is 
shown in Figure 4.8 (a). The residues Arg618, Ser622, and Asn642 suggested by Wong’s 
work are involved in the interactions within the new binding mode. However, the orientation 
of the molecule is reversed. In this binding mode, the tetrazole ring forms hydrogen bonds 
with Arg618 and Ser622 while the furazan carboxylate interacts with Asn642. As for the 
energetically favorable pose of inactive compound 41, the interactions between the tetrazole 
and Arg618 are retained but the conformation of the furazan moiety has been different. As 
shown in Figure 4.8 (b), the furazan carboxylate is exposed to the solvent, resulting in the 
loss of key interactions between the structure and Asn642. 
(a)                                      (b) 
        
Figure 4.8. Preferred docking poses of compounds 2 (a) and 41 (b) in the binding cavity of STAT5-SH2. 
Hydrogen bonds are illustrated as arrows. Pictures were generated by ligandScout 4.2. 
Both of the above speculations conclude the main cause for potency loss of 
5-aminomethyl tetrazole scaffold could be conformation changes to the moiety that interacts 
with Asn642. However, the actual binding mode and the mechanism behind the possible 








5.  Study of 1-aminomethyl tetrazoles 
5.1. Synthesis of 1-aminomethyl tetrazoles 
In order to improve the activity and stability of the scaffold, another possible way is to attach 
different substituents to the 5-position of the tetrazole ring. Because structure extension could 
bring the possibility of binding to additional sites that were beyond reach previously. Besides, 
different substituents at the tetrazole ring could have diverse impacts on the stability of this 
scaffold. The following method was applied to synthesize theses derivatives. 
5.1.1. Synthesis of 4-amino-furazan-3-carboxylic acid 
The fragment 4-amino-furazan-3-carboxylic acid 1 is a necessary building block in the 
synthesis of 1-aminomethyl-5-substituted tetrazoles in this study. A one-pot method 
introduced by Sheremetev et al.114, 115 was applied in the synthesis of compound 1. The 
commercially available ethyl 2-cyanoacetate was used as the starting material. 
 
Scheme 5.1. One-pot synthesis of 4-amino-furazan-3-carboxylic acid 1. 
One potential explanation of the mechanism (Scheme 5.3) is that ethyl 2-cyanoacetate is 
first transformed into an enol intermediate in the presence of orthophosphoric acid. 
Meanwhile, in acidic condition, the nitrite ion is converted to nitrosonium ion (Scheme 5.2), 
which acts as a electrophile to react with the double bond of the enol to give a cyano oxime 
intermediate. The cyano oxime compound is subsequently converted to the dioxime 
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intermediate by treatment with hydroxylamine hydrochloride. Cyclization then happens under 
heating and vigorous stirring. After acidification, approximately two thirds of the amino acid 
product was obtained as white precipitation, which was pure enough for the following 
synthesis. The rest of the product was extracted from the filtrate with ethyl acetate. 
 
Scheme 5.2. Mechanism of nitrosonium ion formation from nitrite ion in acidic condition. 
 
Scheme 5.3. A potential mechanism of 4-amino-furazan-3-carboxylic acid formation. 
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5.1.2. Synthesis of 5-substituted tetrazoles 
The synthesis of 1-aminomethyl tetrazoles proceeded in two steps. A nitrile starting reactant 
was first converted to the corresponding 5-substituted tetrazole compound in the presence of 2 
equivalent of sodium azide (NaN3) and 1.1 equivalent of ammonium chloride. Previously, this 
1,3-dipolar cycloaddition reaction was conducted under normal heating in DMF at 100 °C116 
with a reaction time of 3 h. By utilizing microwave reactor117-119, the reaction time was 
decreased to 30 min. The yield of each compound varies depending on the R group at the 
5-position of the tetrazole ring (Table 5.1).  
 








































Table 5.1. Yields of 5-substituted tetrazole compounds in microwave-assisted reactions. 
Remarkably, products with an O-containing linkage between the tetrazole ring and the 
phenyl group display high yields in the tetrazole formation reactions except for compound 12. 
The reason could be the electron-withdrawing effect of O-containing linkage on the nitrile 
increases its reactivity in the reaction. As positive charge on the the nitrile group is favorable 
to the nucleophilic attack from the azide anion. While the substituents on the phenyl ring 
didn’t show such big influence on the yields, which could attribute to the relatively long 
distance from the nitrile group, comparing that between the oxygen atom and the nitrile 
group. 
 
Scheme 5.4. Mechanism of 5-substituted tetrazole formation through concerted 1,3-dipolar cycloaddition. 
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5.1.3. Mannich ligations 
The last step is the Mannich ligation reaction (Scheme 5.5). 4-amino-furazan-3- 
carboxylic acid (1), formaldehyde and a 5-substituted tetrazole were used in this 
three-component reaction. In the beginning compound 1 was not completely soluble in 
acetonitrile. After addition of formaldehyde the suspension gradually became a clear solution, 
indicating the formation of the imine intermediate. The 5-substituted tetrazole building block 
was then added into the solution and the resulting mixture was stirred for 16 h at room 
temperature. Afterwards, the product was isolated by column chromatography. The 
conversion of the starting materials was not complete even enough reaction time was given 
and the reaction temperature was increased, resulting in the low yield of this reaction. The 
incomplete conversion of the reaction could be due to the instability of the products in acidic 
condition, which will be discussed in the stability study section. 
 
 
Scheme 5.5. Synthesis of 1-aminomethyl tetrazoles via Mannich ligation reactions. 
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5.2. Determination of binding activity 
The binding activity of the 1-aminomethyl tetrazoles were measured in competitive FP 
assays using the same protocol introduced in the previous chapter. The IC50 and Ki values of 
the compounds are summarized in Table 5.2. Most of them demonstrate a binding activity in 
low micromolar range, in which compound 24 is the most active with a Ki value of 1.8 µM 
(Figure 5.1). 
 
Compound R IC50 (µM) Ki (µM) 
2 H 7.1 2.2 











































Table 5.2. Summary of the IC50 and Ki values of 1-aminomethyl tetrazoles in FP assays. 
  
Figure 5.1. Binding activity of compound 24 to MBP-STAT5b-SH2 (error bars denote mean ± SD, n = 2). 
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5.3. Stability study of 1-aminomethyl tetrazoles 
The 1-aminomethyl tetrazoles synthesized through Mannich ligation reactions showed good 
binding activity towards STAT5 protein in FP assays. However the scaffold was found 
unstable in aqueous medium with acidic pH. For example, after purification the above 
products were measured by LC-MS with acidic mobile phase (0.1% formic acid additive in 
acetonitrile/water), most of the resulting chromatograms displayed three main signals that 
belonged to the product, the corresponding 5-substituted tetrazole and the furazan compound 
1 respectivly (Figure 5.2). This phenomenon indicated that the products were decomposed 
back into the starting materials of the corresponding ligation reactions. Only compounds 28 
and 29 didn’t show significant decomposition under the above condition. A possible 
mechanism is shown in Scheme 5.6. The break of the bond between aminomethyl and 
tetrazole ring gives iminium ion and 5-substituted tetrazolate ion intermediates. In the 
presence of enough acidity and water, they are transformed into fragment 1 and 5-substituted 
tetrazole respectively. The instability of the inhibitors could have a negative effect on their 
biological activity. Because in the HRMS measurement, the mass of the theoretical 
ligand-protein complex couldn’t be found after sufficient incubation in the FP buffer, which 
excludes the possibility of irreversible binding mode. 
 
Figure 5.2. Compound 3 was decomposed in the process of chromatography using acidic mobile phase 
(wavelength = 254 nm). 
To clarify how the environmental acidity and different substituents on the tetrazole 
influence the stability of the compounds and to find out possible stable molecules, an LC-MS 
based stability study was carried out. Compounds 27 and 30 were excluded because they 
precipitated in buffer. The testing compounds were first dissolved in a 20 mM ammonium 
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bicarbonate buffer at pH 7.4 to concentrations range from 0.5 mM to 1.5 mM (cn). The 
resulting solutions were measured immediately by LC-MS at 254 nm wavelength with a 10 
mM ammonium bicarbonate containing mobile phase (acetonitrile/water) at pH 7.4. No 
significant decompositions were found on the resulting chromatograms (e.g. compound 3, 
Figure 5.4). The absorbance peaks of the testing compounds were then integrated and the 
nominal extinction coefficients (εn) of them under the above condition were calculated 
according to the Beer–Lambert law (Equation 5.1), which was used to reflect the 
decomposition degrees of the compounds in this work. 
 
 
Figure 5.3. Structures of the testing compounds in the LC-MS based stability study. 
 
Figure 5.4. Chromatogram of compound 3 at 254 nm using acetonitrile/water mobile phase containing 10 
mM ammonium bicarbonate at pH 7.4. 







Equation 5.1. Calculation of the nominal extinction coefficients (εn) of the testing compounds at 254 nm 
according to the Beer-Lambert law, where AI is the integrated absorbance of a testing compound, cn is the 
nominal concentration of the compound, and l is the path length of the DAD flow cell in the LC system. 
The next step was to investigate the influences of acidity and different substituents on the 
stability of these compounds. 20 mM ammonium acetate solution was chosen as the medium 
to dissolve the testing compounds as it has an acidic buffer range of pH 5.8 to 3.8, which best 
met the needs of this experiment120. 10 mM ammonium bicarbonate containing 
acetonitrile/water at pH 7.4 remained as the mobile phase of the LC system to minimize the 
possibility of compound decomposition in the process of chromatography. Each of the eleven 
compounds was first dissolved in DMSO to give a 20 mM stock solution, which was then 
diluted by four 20 mM ammonium acetate solutions at pH 5.8, 4.8, 3.8 and 2.8 respectively to 
the concentration of 1 mM (cn). After 30 min, 3 µl of each solution was injected into the 
LC-MS system for measurement (e.g. compound 24, Figure 5.5). 
 
Figure 5.5. Chromatograms of compound 24 at 254 nm after dissolution in buffers with different pH 
values. 
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The absorbance peaks of the testing compounds on the resulting chromatograms were 
integrated and the nominal extinction coefficients (εn) of the compounds at different pH 
values were calculated using Equation 5.1. To reflect the decomposition degree more directly, 
the εn values of each compound under four acidic conditions were then divided by the 
corresponding εn at pH 7.4 to represent the relative absorbances (Ar), which are shown in 
Figure 5.6. 
 
Figure 5.6. Decomposition degrees of compounds 2, 3, 18–26 in acidic buffer solutions with different pH 
values (error bars denote mean ± SD, n = 2). 
In the above graph, a larger Ar value denotes that more molecules of a certain compound 
are intact, in other words, less decomposition has happened when compared with a smaller Ar. 
As the result shows, the acidity of the aqueous medium obviously has a negative effect on the 
stability of 1-aminomethyl tetrazoles. For each compound, the decomposition degree is 
extended as the acidity of the buffer increases. Among the eleven compounds, 24 and 25 are 
the most stable ones in all the four acidic conditions, indicating phenoxyalkyl substituents at 
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the 5-position of the tetrazole ring are favorable for the structure’s stability. As for the 
benzyl-substituted compounds 3, 19, 20, 21, and 22, electron-withdrawing groups on the 
phenyl ring are beneficial to the stability as 19 and 22 are generally more stable than 3. While 
the decomposition degrees of 20 and 21 are greater than 3 suggesting that electron donating 
groups on the phenyl ring are unfavorable for maintaining the stability. When comparing the 
stability differences among compounds 3, 18 ,and 23, long aliphatic chain on the tetrazole 
ring is obviously a disadvantage. Because 23, containing three methylene groups, is the least 
stable one in the three compounds and even is in the all eleven compounds. While 3, which 
possesses only one methylene group, is more stable than 18 and 23. This interpretation could 
also explain the reason that compound 26 is less stable than 24 and 25 in this experiment. To 
sum up, the substituent at the 5-position of the tetrazole ring has a remarkable influence on 
the stability of 1-aminomethyl tetrazoles. Electron-withdrawing effect is beneficial for the 
stability of the scaffold in acidic conditions while electron donating effect is a disadvantage. 
These findings are consistent with the facts that compounds 28 and 29 are stable in LC-MS 
measurements with acidic mobile phase and compound 2 without 5-substituent on the 
tetrazole ring generally possesses a stability extent between the consequences of the two 
opposite electronic effects. 
In the chromatograms of this stability study, the absorbance peak of each substituted 
tetrazole compound is shown as a doublet, of which the two peaks have identical masses. The 
reason could be that 2,5-disubstituted regioisomers formed from the corresponding 
1,5-disubstituted tetrazoles in the above buffer conditions. The possible mechanism (Scheme 
5.6) of this isomerization could first follow the same step as that in the decomposition 
mechanism to give the iminium cation and the tetrazolate anion intermediates. The subsequent 
nucleophilic attack from the tetraolate anion on the iminium, which is not acid-driven, 
furnishes the corresponding 2,5-disubstituted regioisomer. This mechanism is consistent with 
the fact that decomposition and possible isomerization of the testing compounds exist 
simultaneously in the above acidic conditions according to the chromatograms. 






























































Scheme 5.6. Possible decomposition and isomerization mechanisms of 1,5-disubstituted tetrazoles 
5.4. Validation of binding to STAT5b-SH2 
Considering that compound 24 showed the best activity in FP binding assay, it was chosen for 
a thermal shift assay to validate the binding to STAT5-SH2. The mechanism of this assay is 
that the binding of a ligand can increase the thermal stability of its target protein, leading to a 
shift of melting temperature. Gradually increased temperature allows the protein to unfold and 
expose its hydrophobic surfaces. Fluorescent dye SYPRO Orange then is able to 
nonspecifically bind to the hydrophobic surfaces leading to an increase in fluorescence. By 
recording the variation of fluorescence with increased temperature, the denaturation midpoint 
(melting temperature, Tm) can be determined. An increase of Tm indicates enhancement of 
protein thermal stability due to ligand binding121-124. 
In the presence of SYPRO Orange, MBP-STAT5b-SH2 was treated with serial 
concentration of compound 24 or DMSO. The melting temperature of MBP-STAT5b-SH2 
protein was 48 °C. In contrast, the addition of 24 increased the melting temperature to 58 °C 
(Figure 5.7). On the other hand, when the protein tag MBP was added instead of 
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MBP-STAT5b-SH2 protein in the same condition, the melting temperature of MBP didn’t 
change after incubation with 24. The results further validate that STAT5-SH2 is the binding 
target of 24 and the potential positive role of MBP in the binding event has been excluded. 
(a) 
 
                   (b) 
 
Figure 5.7. Thermal shift assay results of compound 24. (a) Compound 24 bound to MBP-STAT5b-SH2 
leading to an increase of protein melting temperature. (b) No thermal shift was observed indicating 
compound 24 did not bind to MBP. 
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5.5. Binding of compounds to STAT5b N642A 
As mentioned before, Asn642 was crucial to the binding affinity between a ligand and 
STAT5b-SH2. Specifically to this work, the carbonyl and the amide-NH2 of Asn642 were 
responsible for the formation of hydrogen bonds with the active compounds. To further 
confirm the importance of Asn642, the MBP-STAT5b-SH2 N642A protein was generated by 
site-directed mutagenesis. Binding of fluorophore-labeled peptide 5-CF-GpYLSLPPW-NH2 
to STAT5b N642A displayed a KD value of ca. 5 µM65, representing the binding affinity was 
significantly reduced. 
 
Figure 5.8. Binding of phosphopeptide 5-CF-GpYLSLPPW-NH2 to MBP-STAT5b-SH2 N642A65. 
The binding affinity of compound 2 to MBP-STAT5b-SH2 N642A was determined by 
competitive FP assay. A Ki value of 31 µM suggested that the binding affinity of compound 2 
to STAT5b N642A was in a 14 fold decrease in comparison with the activity against wild type 
STAT5b. Similar trend was found in the assay with compound 24, where binding of 
compound 24 and mutant STAT5 protein resulted in a 12 fold decrease of affinity (Figure 
5.9). 
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(a)                          (b) 
 
Figure 5.9. (a) Binding of compound 2 to MBP-STAT5b-SH2 N642A displayed a 14 fold decrease in the 
affinity. (b) Compound 24 showed a Ki value of 22 µM instead of 1.8 µM for the wild type protein. 
These results validate that Asn642 in SH2 domain plays a pivotal role in the binding 
between ligands and STAT5 protein. Although the affinity of phosphopeptide 
5-CF-GpYLSLPPW-NH2 was strongly reduced, the importance of other possible binding sites 
should not be ignored, because compounds 2 and 24 still maintained Ki values of 31 µM and 
22 µM respectively. 
5.6. Inhibitory effect on leukemic cell proliferation 
It has been well demonstrated that internal tandem duplication (ITD) mutation in FMS-like 
tyrosine kinase 3 (FLT3) gene is one of the most frequent genetic abnormalities in acute 
myeloid leukemia (AML) patients40, 125-127. The receptor tyrosine kinase FLT3 with the ITD 
mutation leads to the constitutive activation of STAT5, making it a key factor in the 
pathogenesis of AML. It would be interesting to examine the influence of STAT5 inhibitors on 
AML related cells’ viability. Hence, the biological activity of compounds 3 and 24 were 
further studied in an Alamar Blue assay using human AML cell line MV-4-11, which carries 
the FLT3-ITD mutation. In this assay, the MV-4-11 cells in a 96-well microtiter plate were 
first treated with serial concentration of compounds. After 72 h of incubation, Alamar blue 
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solution was added and the proliferation of the cells was then determined by fluorescence 
spectrophotometry. The result validates the inhibitory effect of the 1-aminomethyl- 





Figure 5.10. The proliferation of MV-4-11 cells was inhibited by compounds 3 (a) and 24 (b) in the 







6.  Summary and outlook 
This work has elaborated the investigation of the tetrazole-containing compounds derived 
from furazan-based phosphate mimetics to discover STAT5 inhibitors with improved potency 
and stability. 
In the first section of this work, 5-aminomethyl tetrazoles were designed based on the 
scaffold of the lead compounds 2 and 3, and four synthetic routes were planned. Due to the 
low reactivity of the amino group in fragment 1 as a nucleophile, the first three routes failed 
to give the expected products. In the fourth route, a Strecker-type reaction was used to first 
give the key intermediate 40. The nitrile functional group in 40 was then used to form the 
tetrazole ring via 1,3-dipolar cycloaddition reaction. In this way, the 5-aminomethyl tetrazole 
scaffold was obtained. The synthesis of the stable 5-aminomethyl tetrzaole scaffold has been 
thoroughly studied and discussed although it is inactive to the expected target. The possible 
conformation reasons for the inactivation was speculated in docking experiments.  
In the second section, efforts were made to investigate the 1-aminomethyl tetrazole 
scaffold. A series of 1-aminomethyl tetrazoles with different substituents at the 5-position of 
the tetrazole ring was synthesized. Most of the 1-aminomethyl-5-substituted tetrazoles have a 
binding activity to STAT5 SH2 domain in the low micromolar range, in which compound 24 
is the most active one with a Ki value of 1.8 μM although the 5-substituent on the tetrazole 
ring has limited influence on the binding activity. To understand how the substituents on the 
tetrazole ring influence the scaffold’s stability under acidic conditions, a systematic stability 
study was carried out on LC-MS. The electron-withdrawing 5-substituents were proved to be 
able to stabilize the scaffold and compounds 19, 22, 24, and 25 were found more stable than 
the lead compounds. To further verify the binding to STAT5, a thermal shift assay was 
conducted. The melting temperature of MBP-STAT5b-SH2 was increased by 10 °C after 
addition of compound 24, proving the binding to STAT5-SH2 exist. The importance of 
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Asn642 in STAT5-SH2 was also testified by using STAT5b N642A in the FP binding assay, in 
which the testing compounds 2 and 24 showed significant potency loss. It reveals the critical 
role of Asn642 in ligand-STAT5 interactions. Compounds 3 and 24 also showed inhibitory 
effect against the survival of human AML related cells in the cell proliferation assay. 
Looking into the future, further studies on the molecular scaffolds elaborated in this 
work are still needed. For the 5-aminomethyl tetrazoles, strict computational and 
crystallographic methods can be reliable ways to reveal the cause for potency loss, which 
would be significant to the rational design of related STAT5 inhibitors. As for the 
1-aminomethyl tetrazoles, efforts should be paid to the furazan moiety in order to discover 
more favorable STAT5 ligands. Because the 5-substituent on the tetrazole ring didn’t show a 
significant effect on the activity and the space for modification on the tetrazole is already very 
limited. Thus, structure variations such as amidation on the furazan carboxylate and 
replacement of the furazan ring by other heterocycles are reasonable ways for further 
















7.  Materials and methods 
7.1. Materials 
All chemicals and reagents were purchased from standard suppliers like ABCR (Karlsruhe, 
Germany), Alfa Aeser (Karlsruhe, Germany), Bachem (Bubendorf, Switzerland), Carl Roth 
(Karlsruhe, Germany), Fisher Scientific (Schwerte, Germany), Merck (Darmstadt, Germany), 
Sigma-Aldrich (Taufkirchen, Germany), and VWR (Darmstadt, Germany) and were used 
without further purification. All reactions described and performed under dry conditions 
followed the conditions of Schlenk technology. The anhydrous solvents were purchased in 
HPLC grade from VWR and Merck (Darmstadt, Germany) and were further purified by a 
MB-SPS-800 solvent purification system from M. Braun (Garching, Germany). Water for 
HPLC purification and for MS analysis was obtained via a LaboStar ™ UV 2 ultrapure water 
system from Siemens (Barsbüttel, Germany). Deuterated solvents for NMR spectroscopy 
were purchased from Carl Roth (Kastellaun, Germany), Deutero (Kastellaun, Germany) and 
Sigma-Aldrich (Taufkirchen, Germany). 
7.2. Used devices and methods 
7.2.1. Microwave-assisted synthesis 
Microwave-assisted syntheses were carried out on a Initiator+ instrument from Biotage 
(Uppsala, Sweden). The volume of the septa-sealed, pressure-stable reaction vials used ranges 
from 5 mL to 20 mL. 




Thin layer chromatograms were performed on silica gel 60 F254 coated aluminum plates 
from Merck. Compound visualizations were achieved by UV light with wavelengths of 254 
nm and 366 nm. 
7.2.3. Column chromatographic separation 
Column chromatographic separations were carried out in MPLC system with automated 
fraction collections. Biotage Isolera One system and prepackaged Biotage SNAP cartridges 
were used. 
7.2.4. Preparative HPLC 
Purifications of the synthesized compounds by preparative HPLC were performed on an 
Agilent 1260 Infinity Binary LC System. A C18 HTec, 5 μm column from Macherey Nagel 
(Düren, Germany) was used for the separation. The eluent was a mixture of acetonitrile/water 
with a 0.1% trifluoroacetic acid additive. The compounds (≤ 100 mg) to be purified were 
dissolved in a maximum of 10 mL acetonitrile/water (variable ratios depending on solubility, 
acetonitrile% ≤ 50%). The separations were carried out with linear gradients (5% → 95% 
acetonitrile over a period of 25–35 min at a flow rate of 30 mL/min). 
7.2.5. NMR spectroscopy 
The NMR spectra were recorded on an ECP500 (Jeol, Akishima, Japan) and an AVANCE III 
700 (Bruker, Billerica, MA, USA). The values of chemical shift δ are given in ppm. The 
reference signals used were the deuterated solvents signal. The 13C spectra were recorded by 
using 1H broadband decoupling. The multiplicities of signals were described as follows: s 
(singlet), d (doublet), t (triplet), q (quartet) and m (multiplet). Evaluations of the spectra were 
performed by MestReNova 10 (Mestrelab Research, S. L., Santiago de Compostela, Spain). 
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7.2.6. LC-MS analysis 
LC-MS analyses were carried out on an Agilent 1100 series system from Agilent (Santa Clara, 
CA, USA). The detections were carried out by a diode array detector (DAD) at different 
wavelengths. The coupled single quadrupole mass spectrometer used electrospray ionization 
(ESI) to ionize the molecules. The samples to be measured were dissolved in a mixture of 
acetonitrile/water (1: 1). The mobile phase was a mixture of acetonitrile/water with a 0.1% 
formic acid additive. The elutions were carried out with a linear gradient (5% → 99% 
acetonitrile) for 5.5 min, followed by a 4.5 min isocratic elution phase at a flow rate of 1 
mL/min. A Phenomenex Luna-C18 (100 × 4.6 mm, 3 μm) column and an Agilent Pursuit XRs 
C8 (100 × 4.6 mm, 3 μm) column were used for separation. 
In the stability study, the mobile phase used was a mixture of acetonitrile/water (pH 7.4), 
which contained 10 mM ammonium acetate or ammonium bicarbonate instead of formic acid 
additive. To change the acidic condition to physiological condition, acidic mobile phase was 
first replaced with neutral acetonitrile/water mixture. The bubbles generated in the storage 
bottles and pipelines during the replacement should be removed. After being disconnected 
from the DAD, the column to be used was washed with neutral mobile phase at a flow rate of 
0.5 mL/min until a stable pressure was achieved. The column was washed for another 15 min 
at 1 mL/min. Then, the same procedures were carried out to replace the neutral mobile phase 
with the physiological one. The DAD should be connected to the column again before 
measurement. 
7.2.7. LC-HRMS analysis 
High resolution mass spectra were measured on an ESI-QTOF iFunnel Model 6550 
spectrometer coupled with an HPLC system of the Series Infinity II 1290.  
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7.2.8. Melting point determination 
The melting points of the synthesized compounds were determined by a Büch B-545 
instrument. 
7.2.9. Molecular docking 
Molecular Operating Environment (MOE 2019.0102) was used to prepare the homology 
model of STAT5-SH2 and small molecules. The prepared protein file in PDB format and 
ligands file in SDF format were loaded into GOLD 5.7.0 for docking. LigandScout 4.2 was 
used to analyze the docking results. 
7.3. Biochemical methods 
7.3.1. Protein expression and purification 
STAT5b and STAT5b N642A proteins were kindly expressed and purified by Dr. Arkona and 
Bergemann. Expression of the truncated version of STAT5b (aa 137-747) cloned into a 
modified pQE70, with N-terminal MBP-tag and C-terminal His-tag was conducted on 
autoinduction medium (overnight express/Novagen, cat. 71491, Merck, Germany). Cells were 
grown to an optical density (O.D.) of 0.3 at 37 °C, then the temperature was reduced to 20 °C 
for further 48 h of expression. Comparable soluble expression levels were obtained with 
Rosetta2 (DE3) (cat.71400, Novagen, Merck, Germany) and BL21 (DE3) pLysS (cat.69451, 
Novagen, Merck, Germany). The protein was purified by Ni-chelating chromatography 
followed by gel filtration (Superdex 200/10 mM HEPES pH 7.8, 100 mM NaCl, 1 mM EDTA, 
1 mM DTT, 10% glycerol).A yield of 15 mg MBP-STAT5b-His per liter of culture was 
obtained and aliquots (200 μl of 3.2 mg ml-1) were quick-frozen and stored at –80 °C, ready 
for use. Site-directed mutagenesis was performed using PCR-based site directed mutagenesis 
with high fidelity PWO DNA polymerase (cat.11644947001, Roche, Germany) and confirmed 
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by Sanger sequencing (Supplementary Figure 9). The mutant proteins were expressed and 
purified as described above. Purified mutant proteins were further concentrated by 
ultrafiltration (Amicon 30-kDa MW cut-off; cat. UFC903024, Milipore Corporation, Billerica, 
MA). 
7.3.2. Fluorophore-labeled peptide synthesis 
The carboxyfluoresceine-labeled phosphotyrosine octapeptide 5-CF-GpYLSLPPW- NH2 was 
kindly synthesized by coworker Accorsi. Peptide synthesis was conducted on Rink amide 
resin using Fmoc-strategy. PP/PE syringes equipped with a PE-frit were used as reaction 
vessels. Fmoc-amino acids and reagents were purchased from common suppliers. The 
coupling reactions were monitored using the Kaiser test and quantified via UV-photometric 
determination of the dibenzofulvene product following to Fmoc cleavage. The unnatural 
amino acid N-Fmoc-O-benzyl-phosphotyrosine was pre-activated with TBTU and DIPEA. 
First, N-Fmoc-O-benzyl-phosphotyrosine (4 eq) was dissolved in a minimal amount of DMF. 
Then, DIPEA (2 eq) was added and the solution was mixed for 2 min. Afterwards, TBTU (4 
eq) was added, the solution was mixed for 3 min and pipetted to the resin. After 4 h the resin 
was washed and the conversion was analyzed with the Kaiser test.The first amino acid after 
incorporation of N-Fmoc-O-benzyl-phosphotyrosine was coupled with full conversion using 
the combination of Fmoc-AA-OH/TBTU/DIPEA (4 eq/4 eq/4 eq) for activation. Subsequent 
coupling steps were conducted with DIC/HOBt activation. The resin was washed after every 
coupling and cleavage procedure. First, the resin was washed with 5 syringe volumes of DMF, 
then with 5 volumes of THF, DCM and Et2O. The Fmoc-group was cleaved by using a 
DBU/DMF (2:98 v/v) solution. The resin was suspended in the basic cocktail, shaken and 
washed. 5-carboxyfluorescein (10 eq.) was pre-activated with DIC/HOBt (10 eq/10 eq) for 2 
min and pipetted to the resin. After 1 h, the resin was washed and DBU/DMF (2:98 v/v) was 
added to cleave formed CF-oligomers. After 15 min the resin was washed and again mixed 
with DBU/DMF. This procedure was repeated until the solution stayed clear. The 
phosphotyrosine-containing peptide was cleaved with 95% TFA/water and shaken for 2 h. 
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The cleaved peptide was filtered and the remaining resin was washed with TFA. The TFA was 
removed with a stream of dry nitrogen and the residue was dried in high vacuum. The peptide 
purified with the standard HPLC buffer (0.1% TFA in acetonitrile/water). The product 
fractions were directly lyophilized affording an orange powder which was dissolved in water 
and stirred over Amberlite resin (IR120 sodium form) for 1 h. The resin was filtered off and 
the filtrate was lyophilized to yield the sodium salt as a red-orange powder. 
7.3.3. Fluorescence polarization assay 
Fluorescence polarization experiments were performed on a Safire II microtiter plate reader 
from Tecan (Crailsheim, Germany). The final concentrations of buffer components were 50 
mM MOPS (pH 7.4), 1 mM EDTA, 0.1% Igepal CA-630, 50 mM NaCl. The final 
concentration of STAT5b used was 190 nM. The final concentration of the 
fluorophore-labeled peptide 5-CF-GpYLSLPPW-NH2 was 10 nM. To carry out the 
measurement, proteins were added to the black 384-well plates (Corning 4514) followed by 
treatment of peptides and varying concentrations of test compounds with a final concentration 
of 5% DMSO. Analysis was conducted after 20 min incubation at room temperature. The 
fluorescence polarization values were expressed in millipolarization units (mP) plotted against 
the logarithms of concentrations using GraphPad Prism 6 software and the IC50 values were 
converted to Ki values using the modified Cheng-Prusoff equation. 
7.3.4. Thermal shift assay 
Thermal shift assays were performed on a real-time PCR setup (Light Cycler 480, Roche 
Diagnostics, Mannheim, Germany) using 96-well PCR plates (cat HSL9901 Bio-Rad 
Laboratories, Richmond, CA).The final concentrations of buffer components used were 300 
mM HEPES (pH 7.4), 175 mM NaCl and 1% DMSO. The final concentration of STAT5 
protein was 500 nM. STAT5 protein was treated with varying concentrations of test 
compounds in the presence of 20x Sypro Orange (cat.S6650, Thermo Scientific, 
Braunschweig, Germany). The PCR plates were sealed with optical seal, shaken for 15 min, 
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and centrifuged before measuring. The temperature was increased from 20 °C to 95 °C during 
the measuring process and the corresponding fluorescence intensity was recorded after every 
0.3 s. The curve fitting and melting temperature calculation were performed using GraphPad 
Prism 6 software. 
7.3.5. Cell proliferation assay 
The cell proliferation assays were conducted by using a Resazurin based In Vitro Toxicology 
Assay Kit (TOX8-1KT, Sigma-Aldrich, Taufkirchen, Germany). MV-4-11 cells (ATCC 
CRL-9591, LGC Standards GmbH, Wesel, Germany) were first planted in triplicate in 
96-well plates (5 × 103 and 1 ×104 per well for adherent and suspension cells respectively) and 
incubated in medium containing 10% FBS overnight. The complete medium of adherent cells 
should be replaced before treatment with compounds. After treated with serial concentration 
of compounds, the cells were incubated for 72 h. The unused wells were added with PBS to 
avoid evaporation effects. Alamar Blue solution was then add into each well and the cells 
were incubated overnight. The fluorescence values were read at an excitation wavelength of 







8.  Synthesis regulations 
8.1. General synthetic methods 
Method 1: 5-substituted-1H-tetrazole formation 
To a solution of the corresponding nitrile compound (6 mmol, 1 eq) in DMF (10 mL) was 
added sodium azide (780 mg, 12 mmol, 2 eq) and ammonium chloride (353 mg, 6.6 mmol, 
1.1 eq). The reaction mixture was stirred and heated under microwave at 140 °C for 30 min. 
After cooling to room temperature, the mixture was treated with water (50 mL), then acidified 
with concentrated HCl to pH 2. The resulting solution was extracted with ethyl acetate (3 × 30 
mL). The combined organic phases were washed with brine, dried over Na2SO4, and 
concentrated under reduced pressure. The residue was purified by column chromatography 
(SiO2, n-hexane/ethyl acetate, 40% → 70% ethyl acetate) to afford pure product. 
Method 2: Mannich ligation reaction 
To a stirred suspension of 4-amino-furazan-3-carboxylic acid (129 mg, 1 mmol, 1 eq) and the 
corresponding 5-substituted-1H-tetrazole (1.5 mmol, 1.5 eq) in acetonitrile (4 mL) was added 
36% formaldehyde solution (154 µL) and glacial AcOH (300 µL). After stirring for 16 h at 
room temperature, the solvent was directly removed under reduced pressure. The residue was 
purified by column chromatography (SiO2, n-hexane/ethyl acetate, 40% → 80% ethyl 
acetate). 
Method 3: preparation of hydrazoic acid solution 
A suspension of sodium azide (1.95 g, 30 mmol) in water (2 ml) was prepared, to which was 
added chloroform or toluene (12 mL) and the mixture was cooled to 0 °C. Concentrated 
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sulfuric acid (800 µL) was then added dropwise to this stirred mixture under cooling. After 
the addition of sulfuric acid, the organic layer was decanted and dried over anhydrous sodium 
sulfate. 
8.2. Synthesized compounds 
4-Amino-furazan-3-carboxylic acid 1 
 
To a stirred suspension of ethyl cyanoacetate (14.2 g, 125 mmol, 1 eq) and sodium nitrite 
(8.7g, 125 mmol, 1 eq ) in a mixture of absolute ethanol (8.5 mL) and water (100 mL) was 
added dropwise 85% H3PO4 (5 mL) at room temperature and stirred overnight. The reaction 
mixture was treated with NaOH (20 g, 500 mmol, 4 eq) and KOH (14 g, 250 mmol, 2 eq) 
afterwards. To the resulting solution was hydroxylamine hydrochloride (34.7 g, 500 mmol, 4 
eq) slowly added at room temperature and heated up to 95 °C. After completion of the 
reaction (2 h), the mixture was cooled to room temperature, quenched with concentrated HCl 
to pH = 2 and a precipitate was formed. After filtration, the precipitate was dried to give a 
white powder as product 1. And the filtrate was extracted with ethyl acetate, the combined 
organic phases were subsequently washed with brine and dried over Na2SO4. The solvent was 
removed under reduced pressure to give another portion of product 1 as an off-white powder. 
Yield: 10.0 g (62%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 6.33 (s, 2H, H-8). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.78 (C-6), 156.94 (C-2), 140.63 (C-1). 
ESI-MS (m/z): [M-H]- calcd for C3H2N3O3-: 128.0 Da; found: 127.9 Da. 
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Melting point: 215 °C 
5-Benzyl-1H-tetrazole 4 
 
5-benzyl-1H-tetrazole 4 was synthesized from 2-phenylacetonitrile (693 µL, 6 mmol, 1 eq) 
according to Method 1 as a white solid. 
Yield: 390 mg (41%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.56 – 6.94 (m, 5H, H-12, H-8, H-9, H-11, H-10), 
4.29 (s, 2H, H-6). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 146.95 (C-1), 136.51 (C-7), 129.28 (C-9, C-11), 
129.22 (C-8, C-12), 127.57 (C-10), 29.47 (C-6). 
ESI-MS (m/z): [M+H]+ calcd for C8H9N4+: 161.1 Da; found: 161.0 Da. 
Melting point: 125 °C 
5-Phenethyl-1H-tetrazole 5 
 
5-phenethyl-1H-tetrazole 5 was synthesized from 3-phenylpropanenitrile (786 µL, 6 mmol, 1 
eq) according to Method 1 as a white solid. 
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Yield: 480 mg (46%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.41 – 7.15 (m, 5H, H-9, H-10, H-11, H-12, 
H-13), 3.19 (t, J = 7.8 Hz, 2H, H-7), 3.05 (t, J = 7.8 Hz, 2H, H-1). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 155.97 (C-2), 140.53 (C-8), 128.97 (C-10, C-12), 
128.82 (C-9, C-13), 126.84 (C-11), 33.28 (C-7), 25.15 (C-1). 
ESI-MS (m/z): [M+H]+ calcd for C9H11N4+: 175.1 Da; found: 175.3 Da. 
Melting point: 102 °C 
5-(3-Chlorobenzyl)-1H-tetrazole 6 
 
5-(3-chlorobenzyl)-1H-tetrazole 6 was synthesized from 2-(3-chlorophenyl)acetonitrile (709 
µL, 6 mmol, 1 eq) according to Method 1 as a white solid. 
Yield: 861 mg (74%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.54 – 7.30 (m, 3H, H-8, H-10, H-12), 7.24 (ddd, 
J = 7.3, 2.0, 1.3 Hz, 1H, H-11), 4.33 (s, 2H, H-6). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 162.92 (C-1), 138.86 (C-7), 133.77 (C-9), 
131.11 (C-11), 129.27 (C-10), 128.09 (C-8), 127.63 (C-12), 29.01 (C-6). 
ESI-MS (m/z): [M+H]+ calcd for C8H8ClN4+: 195.0 Da; found: 195.0 Da. 
Melting point: 139 °C 





5-(4-methylbenzyl)-1H-tetrazole 7 was synthesized from 2-(p-tolyl)acetonitrile (810 µL, 6 
mmol, 1 eq) according to Method 1 as a white solid. 
Yield: 683 mg (65%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.23 – 7.04 (m, 4H, H-8, H-9, H-11, H-12), 4.23 
(s, 2H, H-6), 2.26 (s, 3H, H-13). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 152.70 (C-1), 136.69 (C-10), 133.41 (C-7), 
129.81 (C-9, C-11), 129.08 (C-8, C-12), 29.06 (C-6), 21.16 (C-13). 
ESI-MS (m/z): [M+H]+ calcd for C9H11N4+: 175.1 Da; found: 175.3 Da. 
Melting point: 161 °C 
5-(4-Methoxybenzyl)-1H-tetrazole 8 
 
5-(4-methoxybenzyl)-1H-tetrazole 8 was synthesized from 2-(4-methoxyphenyl) acetonitrile 
(814 µL, 6 mmol, 1 eq) according to Method 1 as a white solid. 
Yield: 470 mg (41%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.19 (d, J = 8.7 Hz, 2H, H-8, H-12), 6.90 (d, J = 
8.7 Hz, 2H, H-9, H-11), 4.21 (s, 2H, H-6), 3.72 (s, 3H, H-14). 
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13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 159.37, 158.85 (C-1), 130.31 (C-8, C-12), 
128.31 (C-7), 114.68 (C-9, C-11), 55.64 (C-14), 28.61 (C-6). 
ESI-MS (m/z): [M+H]+ calcd for C9H11N4O+: 191.1 Da; found: 191.0 Da. 
Melting point: 159 °C 
5-(3-Fluorobenzyl)-1H-tetrazole 9 
 
5-(3-fluorobenzyl)-1H-tetrazole 9 was synthesized from 2-(3-fluorophenyl)acetonitrile (697 
µL, 6 mmol, 1 eq) according to Method 1 as a white solid. 
Yield: 698 mg (66%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.38 (td, J = 7.9, 6.3 Hz, 1H, H-11), 7.25 – 6.98 
(m, 3H, H-12, H-8, H-10), 4.33 (s, 2H, H-6). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 163.73 (C-9), 161.79 (C-1), 139.17 (C-7), 
131.20 (d, J = 8.3 Hz, C-11), 125.45 (d, J = 2.9 Hz, C-12), 116.22 (d, J = 21.8 Hz, C-8), 
114.46 (d, J = 20.8 Hz, C-10), 29.12 (C-6). 
ESI-MS (m/z): [M+H]+ calcd for C8H8FN4+: 179.1 Da; found: 179.0 Da. 
Melting point: 136 °C 
5-(3-Phenylpropyl)-1H-tetrazole 10 




5-(3-phenylpropyl)-1H-tetrazole 10 was synthesized from 4-phenylbutanenitrile (911 µL, 6 
mmol, 1 eq) according to Method 1 as a white solid. 
Yield: 760 mg (67%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.49 – 6.94 (m, 5H, H-11, H-13, H-12, H-14, 
H-10), 2.99 – 2.74 (m, 2H, H-8), 2.74 – 2.56 (m, 2H, H-1), 2.00 (p, J = 7.7 Hz, 2H, H-7). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 155.89 (C-2), 141.70 (C-9), 128.94 (C-11, C-13), 
128.93 (C-10, C-14), 126.51 (C-12), 34.83 (C-8), 29.24 (C-7), 22.78 (C-1). 
ESI-MS (m/z): [M+H]+ calcd for C10H13N4+: 189.1 Da; found: 189.0 Da. 
Melting point: 92 °C 
5-(Phenoxymethyl)-1H-tetrazole 11 
 
5-(phenoxymethyl)-1H-tetrazole 11 was synthesized from 2-phenoxyacetonitrile (733 µL, 6 
mmol, 1 eq) according to Method 1 as a white solid. 
Yield: 961 mg (91%) 
8. Synthesis regulations 
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1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.38 – 7.27 (m, 2H, H-10, H-12), 7.07 (dt, J = 7.8, 
1.0 Hz, 2H, H-9, H-13), 7.04 – 6.96 (m, 1H, H-11), 5.49 (s, 2H, H-1). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 157.98 (C-8), 154.14 (C-2), 130.21 (C-10, C-12), 
122.23 (C-11), 115.39 (C-9, C-13), 59.82 (C-1). 
ESI-MS (m/z): [M+H]+ calcd for C8H9N4O+: 177.1 Da; found: 177.0 Da. 
Melting point: 128 °C 
5-(2-Phenoxyethyl)-1H-tetrazole 12 
 
5-(2-phenoxyethyl)-1H-tetrazole 12 was synthesized from 3-phenoxypropanenitrile (883 mg, 
6 mmol, 1 eq) according to Method 1 as a white solid. 
Yield: 173 mg (15%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.41 – 7.06 (m, 2H, H-11, H-13), 7.06 – 6.68 (m, 
3H, H-10, H-12, H-14), 4.35 (t, J = 6.2 Hz, 2H, H-7), 3.37 (t, J = 6.2 Hz, 2H, H-1). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.10 (C-9), 158.61 (C-2), 130.09 (C-11, C-13), 
121.48 (C-12), 115.09 (C-10, C-14), 65.17 (C-7), 24.24 (C-1). 
ESI-MS (m/z): [M+H]+ calcd for C9H11N4O+: 191.1 Da; found: 191.0 Da. 
Melting point: 133 °C 
2-Phenethoxyacetonitrile 13 




To a solution of 2-phenylethanol (3.6 mL, 30 mmol, 1 eq) in dry THF (25 mL) was added 60% 
sodium hydride (1.32 g, 33 mmol, 1.1 eq) slowly at 0 °C. After 30 min of stirring 
2-bromoacetonitrile (2.2 mL, 30 mmol, 1 eq) was added and the resulting mixture was stirred 
overnight. After completion of the reaction, the mixture was quenched and filtered. The 
filtrate was concentrated under reduced pressure and purified by column chromatography 
(SiO2, n-hexane/ethyl acetate, 5% → 20% ethyl acetate) to give pure product 13 as a colorless 
oil. 
Yield: 1.08 g (22%) 
5-(Phenethoxymethyl)-1H-tetrazole 14 
 
5-(phenethoxymethyl)-1H-tetrazole 14 was synthesized from 2-phenethoxyacetonitrile 13 
(967 mg, 6 mmol, 1 eq) according to Method 1 as a white solid. 
Yield: 718 mg (98%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.38 – 7.04 (m, 5H, H-12, H-14, H-13, H-11, 
H-15), 4.84 (s, 2H, H-1), 3.72 (t, J = 7.0 Hz, 2H, H-8), 2.87 (t, J = 7.0 Hz, 2H, H-9). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 154.57 (C-2), 139.07 (C-10), 129.38 (C-11, 
C-15), 128.83 (C-12, C-14), 126.71 (C-13), 72.01 (C-8), 61.62 (C-1), 35.74 (C-9). 
8. Synthesis regulations 
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ESI-MS (m/z): [M+H]+ calcd for C10H13N4O+: 205.1 Da; found: 205.3 Da. 
Melting point: 76 °C 
5-((4-Methoxyphenoxy)methyl)-1H-tetrazole 15 
 
5-((4-methoxyphenoxy)methyl)-1H-tetrazole 15 was synthesized from 
2-(4-methoxyphenoxy)acetonitrile (979 mg, 6 mmol, 1 eq) according to Method 1 as a white 
solid. 
Yield: 1.20 g (97%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.08 – 6.94 (m, 2H, H-9, H-13), 6.94 – 6.78 (m, 
2H, H-10, H-12), 5.41 (s, 2H, H-6), 3.70 (s, 3H, H-15). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 155.99 (C-2), 154.74 (C-11), 151.95 (C-8), 
116.62 (C-9, C-13), 115.26 (C-10, C-12), 60.54 (C-6), 55.95 (C-15). 
ESI-MS (m/z): [M+H]+ calcd for C9H11N4O2+: 207.2 Da; found: 207.0 Da. 
Melting point: 147 °C 
3-(Benzyloxy)benzonitrile 16 




To a solution of 3-hydroxybenzonitrile (360 mg, 3 mmol, 1 eq) in acetone (10 mL) was added 
benzyl bromide (535 µL, 4.5 mmol, 1.5 eq) and potassium carbonate (620 mg, 4.5 mmol, 1.5 
eq). The resulting mixture was stirred at room temperature overnight. After completion of the 
reaction, the mixture was filtered. The filtrate was concentrated under reduced pressure and 
purified by column chromatography (SiO2, n-hexane/ethyl acetate, 2% → 20% ethyl acetate) 
to give pure product 16 as a white solid. 
Yield: 579 mg (92%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.73 – 7.07 (m, 9H, H-3, H-2, H-11, H-15, H-12, 
H-14, H-6, H-13, H-4), 5.17 (s, 2H, H-9). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 159.04 (C-5), 136.90 (C-10), 131.44 (C-3), 
129.07 (C-12, C-14), 128.64 (C-13), 128.45 (C-11, C-15), 125.26 (C-2), 121.20 (C-6), 119.22 
(C-4), 118.33 (C-7), 112.82 (C-1), 70.26 (C-9). 
ESI-MS (m/z): [M+H]+ calcd for C14H12NO+: 210.1 Da; found: 210.0 Da. 
Melting point: 40 °C 
5-(3-(Benzyloxy)phenyl)-1H-tetrazole 17 
 
8. Synthesis regulations 
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5-(3-(benzyloxy)phenyl)-1H-tetrazole 17 was synthesized from 3-(benzyloxy)-benzonitrile 16 
(1.26 g, 6 mmol, 1 eq) according to Method 1 as a white solid. 
Yield: 1.51 g (99%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.96 – 6.97 (m, 9H, H-7, H-15, H-19, H-16, H-18, 
H-8, H-11, H-17, H-9), 5.21 (s, 2H, H-13). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 159.41 (C-10), 150.02 (C-2), 137.23 (C-14), 
131.34 (C-8), 129.07 (C-16, C-18), 128.55 (C-17), 128.33 (C-15, C-19), 121.93 (C-6), 119.99 
(C-7), 118.36 (C-9), 113.70 (C-11), 70.06 (C-13). 
ESI-MS (m/z): [M+H]+ calcd for C14H13N4O+: 253.1 Da; found: 253.0 Da. 
Melting point: 213 °C 
4-(((1H-Tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 2 
 
4-(((1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 2 was synthesized from 0.45 
M 1H-tetrazole in acetonitrile (3.3 mL, 1.5 mmol, 1.5 eq) according to Method 2 as a white 
solid. 
Yield: 130 mg (62%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 9.44 (s, 1H, H-12), 7.91 (t, J = 7.0 Hz, 1H, H-8), 
5.91 (d, J = 7.0 Hz, 2H, H-10). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 169.84 (C-6), 160.16 (C-2), 155.80 (C-12), 
144.58 (C-1), 57.19 (C-10). 
8. Synthesis regulations 
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ESI-MS (m/z): [M+Na]+ calcd for C10H13N4O+: 234.0 Da; found: 234.0 Da. 
Melting point: 154 °C 
4-(((5-Benzyl-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 3 
 
4-(((5-benzyl-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 3 was synthesized 
from 5-benzyl-1H-tetrazole 4 (240 mg, 1.5 mmol, 1.5 eq) according to Method 2 as a white 
solid. 
Yield: 92 mg (31%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.89 (t, J = 6.6 Hz, 1H, H-8), 7.32 – 7.19 (m, 5H, 
H-18, H-22, H-19, H-21, H-20), 5.88 (d, J = 6.6 Hz, 2H, H-10), 4.48 (s, 2H, H-16). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.11 (C-2), 155.55 (C-6), 155.03 (C-12), 
140.46 (C-17), 135.77 (C-1), 129.29 (C-19, C-21), 129.05 (C-18, C-22), 127.45 (C-20), 56.47 
(C-10), 28.68 (C-16). 
ESI-MS (m/z): [M+Na]+ calcd for C12H11N7O3Na+: 324.1 Da; found: 324.0 Da. 
Melting point: 159 °C 
4-(((5-Phenethyl-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 
18 




4-(((5-phenethyl-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 18 was 
synthesized from 5-phenethyl-1H-tetrazole 5 (261 mg, 1.5 mmol, 1.5 eq) according to Method 
2 as a white solid. 
Yield: 111 mg (35%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.89 (t, J = 6.5 Hz, 1H, H-8), 7.52 – 6.99 (m, 5H, 
H-20, H-22, H-19, H-23, H-21), 5.75 (d, J = 6.5 Hz, 2H, H-10), 3.50 – 3.16 (m, 2H, H-16), 
3.13 – 2.92 (m, 2H, H-17). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.21 (C-2), 155.68 (C-6), 155.58 (C-12), 
140.71 (C-18), 140.56 (C-1), 129.00 (C-19, C-23), 128.92 (C-20, C-22), 126.86 (C-21), 56.03 
(C-10), 32.91 (C-17), 24.73 (C-16). 
ESI-HRMS (m/z): [M+H]+ calcd for C13H14N7O3+: 316.1158 Da; found: 316.1151 Da. 
Melting point: 177 °C 
4-(((5-(3-Chlorobenzyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3- 
carboxylic acid 19 
 
8. Synthesis regulations 
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4-(((5-(3-chlorobenzyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 19 was 
synthesized from 5-(3-chlorobenzyl)-1H-tetrazole 6 (240, 1.5 mmol, 1.5 eq) according to 
Method 2 as a white solid. 
Yield: 42 mg (13%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.92 (t, J = 6.4 Hz, 1H, H-8), 7.33 – 7.26 (m, 3H, 
H-21, H-18, H-20), 7.20 (dd, J = 3.6, 1.7 Hz, 1H, H-22), 5.90 (d, J = 6.7 Hz, 2H, H-10), 4.49 
(s, 2H, H-16). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.21 (C-6), 155.58 (C-2), 154.63 (C-12), 
140.70 (C-17), 138.26 (C-1), 133.61 (C-19), 130.83 (C-21), 128.99 (C-20), 128.91 (C-22), 
126.85 (C-18), 56.55 (C-10), 32.91 (C-16). 
ESI-HRMS (m/z): [M+H]+ calcd for C12H11ClN7O3+: 336.0612 Da; found: 336.0604 Da. 
Melting point: 130 °C 
4-(((5-(4-Methylbenzyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3- 
carboxylic acid 20 
 
4-(((5-(4-methylbenzyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 20 was 
synthesized from 5-(4-methylbenzyl)-1H-tetrazole 7 (261 mg, 1.5 mmol, 1.5 eq) according to 
Method 2 as a white solid. 
Yield: 112 mg (35%) 
8. Synthesis regulations 
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1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.86 (t, J = 6.6 Hz, 1H, H-8), 7.18 – 6.96 (m, 4H, 
H-18, H-22, H-19, H-1), 5.86 (d, J = 6.6 Hz, 2H, H-10), 4.42 (s, 2H, H-16), 2.24 (s, 3H, 
H-23). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.12 (C-2), 155.49 (C-6), 155.11 (C-12), 
140.35 (C-20), 136.56 (C-17), 132.66 (C-1), 129.60 (C-19, C-21), 129.10 (C-18, C-22), 56.44 
(C-10), 28.27 (C-16), 21.16 (C-23). 
ESI-HRMS (m/z): [M+H]+ calcd for C13H14N7O3+: 316.1158 Da; found: 316.1154 Da. 
Melting point: 179 °C 
4-(((5-(4-Methoxybenzyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3- 
carboxylic acid 21 
 
4-(((5-(4-methoxybenzyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 21 was 
synthesized from 5-(4-methoxybenzyl)-1H-tetrazole 8 (285 mg, 1.5 mmol, 1.5 eq) according 
to Method 2 as a white solid. 
Yield: 109 mg (33%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.88 (t, J = 6.6 Hz, 1H, H-8), 7.14 (d, J = 8.8 Hz, 
2H, H-18, H-22), 6.82 (d, J = 8.8 Hz, 2H, H-19, H-21), 5.86 (d, J = 6.6 Hz, 2H, H-10), 4.39 (s, 
2H, H-16), 3.71 (s, 3H, H-24). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.13 (C-2), 158.73 (C-6), 155.53 (C-20), 
155.31 (C-12), 140.47 (C-1), 130.35 (C-18, C-22), 127.52 (C-17), 114.49 (C-19, C-21), 56.41 
(C-10), 55.59 (C-24), 27.83 (C-16). 
8. Synthesis regulations 
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ESI-HRMS (m/z): [M+H]+ calcd for C13H14N7O4+: 332.1107 Da; found: 332.1103 Da. 
Melting point: 167 °C 
4-(((5-(3-Fluorobenzyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3- 
























4-(((5-(3-fluorobenzyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 22 was 
synthesized from 5-(3-fluorobenzyl)-1H-tetrazole 9 (267 mg, 1.5 mmol, 1.5 eq) according to 
Method 2 as a white solid. 
Yield: 60 mg (19%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.88 (t, J = 6.6 Hz, 1H, H-8), 7.42 – 6.93 (m, 4H, 
H-21, H-22, H-18, H-20), 5.86 (d, J = 6.6 Hz, 2H, H-10), 4.47 (s, 2H, H-16). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 162.63 (d, J = 244.2 Hz, C-19), 160.09 (C-2), 
155.52 (C-6), 154.62 (C-12), 140.39 (C-1), 138.51 (d, J = 7.5 Hz, C-17), 130.91 (d, J = 8.3 Hz, 
C-21), 125.42 (d, J = 2.6 Hz, C-22), 116.26 (d, J = 21.8 Hz, C-18), 114.32 (d, J = 21.0 Hz, 
C-20), 56.55 (C-10), 28.36 (C-16). 
ESI-HRMS (m/z): [M+H]+ calcd for C12H11FN7O3+: 320.0907 Da; found: 320.0893 Da. 
Melting point: 168 °C 




carboxylic acid 23 
 
4-(((5-(3-phenylpropyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 23 was 
synthesized from 5-(3-phenylpropyl)-1H-tetrazole 10 (282 mg, 1.5 mmol, 1.5 eq) according 
to Method 2 as a white solid. 
Yield: 72 mg (22%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.91 (t, J = 6.6 Hz, 1H, H-8), 7.46 – 7.12 (m, 5H, 
H-21, H-23, H-22, H-20, H-24), 5.80 (d, J = 6.6 Hz, 2H, H-10), 3.18 – 2.85 (m, 2H, H-18), 
2.80 – 2.54 (m, 2H, H-16), 2.14 – 1.88 (m, 2H, H-17). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 13C NMR (126 MHz, DMSO-D6) δ 160.19 
(C-6), 155.91 (C-2), 155.71 (C-12), 141.86 (C-19), 140.59 (C-1), 128.91 (C-20, C-24), 128.87 
(C-21, C-23), 126.48 (C-22), 56.14 (C-10), 34.98 (C-18), 28.87 (C-16), 22.48 (C-17). 
ESI-MS (m/z): [M+Na]+ calcd for C14H15N7O3Na+: 352.1 Da; found: 351.8 Da. 
Melting point: 149 °C 
4-(((5-(Phenoxymethyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3- 
carboxylic acid 24 




4-(((5-(phenoxymethyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 24 was 
synthesized from 5-(phenoxymethyl)-1H-tetrazole 11 (264 mg, 1.5 mmol, 1.5 eq) according 
to Method 2 as a white solid. 
Yield: 146 mg (47%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.90 (t, J = 6.8 Hz, 1H, H-8), 7.33 (t, J = 8.0 Hz, 
2H, H-20, H-22), 7.06 (d, J = 7.9 Hz, 2H, H-19, H-23), 7.01 (t, J = 7.3 Hz, 1H, H-21), 5.99 (d, 
J = 6.8 Hz, 2H, H-10), 5.63 (s, 2H, H-16). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.22 (C-2), 157.89 (C-6), 155.75 (C-18), 
152.27 (C-12), 140.63 (C-1), 130.13 (C-20, C-22), 122.27 (C-21), 115.40 (C-19, C-23), 58.85 
(C-16), 56.99 (C-10). 
ESI-HRMS (m/z): [M+Na]+ calcd for C12H1N7O4Na+: 340.0770 Da; found: 340.0772 Da. 
Melting point: 164 °C 
4-(((5-(2-Phenoxyethyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3- 
carboxylic acid 25 
 
8. Synthesis regulations 
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4-(((5-(2-phenoxyethyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 25 was 
synthesized from 5-(2-phenoxyethyl)-1H-tetrazole 12 (285 mg, 1.5 mmol, 1.5 eq) according 
to Method 2 as a white solid. 
Yield: 120 mg (36%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.95 (t, J = 6.3 Hz, 1H, H-8), 7.28 (t, J = 7.7 Hz, 
2H, H-21, H-23), 6.94 (dd, J = 11.7, 8.0 Hz, 3H, H-20, H-22, H-24), 5.90 (d, J = 6.5 Hz, 2H, 
H-10), 4.39 (t, J = 6.3 Hz, 2H, H-17), 3.58 (t, J = 6.3 Hz, 2H, H-16). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.20 (C-2), 158.59 (C-6), 155.75 (C-19), 
153.86 (C-12), 138.47 (C-1), 130.11 (C-21, C-23), 121.47 (C-22), 115.00 (C-20, C-24), 65.08 
(C-17), 56.35 (C-10), 23.72 (C-16). 
ESI-HRMS (m/z): [2M+Na]+ calcd for C26H26N14O8Na+: 685.1956 Da; found: 685.1995 Da. 
Melting point: 162 °C 
4-(((5-(Phenethoxymethyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3- 
carboxylic acid 26 
 
4-(((5-(phenethoxymethyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 26 was 
synthesized from 5-(phenethoxymethyl)-1H-tetrazole 12 (306 mg, 1.5 mmol, 1.5 eq) 
according to Method 2 as a white solid. 
Yield: 169 mg (49%) 
8. Synthesis regulations 
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1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.78 (t, J = 6.9 Hz, 1H, H-8), 7.35 – 7.15 (m, 5H, 
H-22, H-24, H-23, H-25, H-21), 5.79 (d, J = 6.9 Hz, 2H, H-10), 4.99 (s, 2H, H-16), 3.72 (t, J 
= 6.8 Hz, 2H, H-18), 2.84 (t, J = 6.8 Hz, 2H, H-19). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 163.63 (C-12), 160.23 (C-6), 155.71 (C-2), 
152.92 (C-20), 139.09 (C-1), 129.33 (C-21, C-25), 128.81 (C-22, C-24), 126.72 (C-23), 71.89 
(C-18), 60.86 (C-16), 56.61 (C-10), 35.71 (C-19). 
ESI-HRMS (m/z): [M+H]+ calcd for C14H16N7O4+: 346.1264 Da; found: 346.1292 Da. 
Melting point: 124 °C 
4-(((5-((4-Methoxyphenoxy)methyl)-1H-tetrazol-1-yl)methyl)amino)- 
furazan-3-carboxylic acid 27 
 
4-(((5-((4-methoxyphenoxy)methyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic 
acid 27 was synthesized from 5-((4-methoxyphenoxy)methyl)-1H-tetrazole 15 (309 mg, 1.5 
mmol, 1.5 eq) according to Method 2 as a white solid. 
Yield: 86 mg (25%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] =  7.96 – 7.82 (m, 1H, H-8), 7.06 – 6.96 (m, 2H, 
H-19, H-23), 6.96 – 6.84 (m, 2H, H-22, H-20), 5.98 (d, J = 6.7 Hz, 1H, H-10), 5.41 (s, 1H, 
H-16), 3.70 (s, 3H, H-25). 
8. Synthesis regulations 
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13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.22 (C-2), 155.76 (C-6), 154.75 (C-21), 
152.37 (C-12), 151.95 (C-18), 120.00 (C-1), 116.62 (C-19, C-23), 115.26 (C-20, C-22), 60.54 
(C-16), 59.59 (C-10), 55.95 (C-25). 
ESI-HRMS (m/z): [M+H]+ calcd for C13H14N7O5+: 348.1056 Da; found: 348.1134 Da. 




4-(((5-(pyridin-3-yl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 28 was 
synthesized from 3-(1H-tetrazol-5-yl)pyridine (221 mg, 1.5 mmol, 1.5 eq) according to 
Method 2 as a white solid. 
Yield: 40 mg (14%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 9.22 (s, 1H, H-17), 8.75 (s, 1H, H-8), 8.40 (d, J = 
8.1 Hz, 1H, H-19), 8.13 (t, J = 6.9 Hz, 1H, H-21), 7.61 (dd, J = 7.2, 4.8 Hz, 1H, H-20), 6.18 (d, 
J = 6.8 Hz, 2H, H-10). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 162.66 (C-2), 160.17 (C-6), 155.83 (C-17), 
151.95 (C-12), 147.64 (C-19), 140.74 (C-21), 134.72 (C-1), 125.02 (C-16), 120.00 (C-20), 
62.32 (C-10). 
ESI-HRMS (m/z): [M+H]+ calcd for C10H9N8O3+: 289.0798 Da; found: 289.0795 Da. 
8. Synthesis regulations 
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Melting point: 186 °C 
4-(((5-(Trifluoromethyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3- 
carboxylic acid 29 
 
4-(((5-(trifluoromethyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 29 was 
synthesized from 5-(Trifluoromethyl)-1H-tetrazole hydrate (170 mg, 1.5 mmol, 1.5 eq) 
according to Method 2 as a viscous oil. 
Yield: 146 mg (54%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 8.18 (t, J = 7.1 Hz, 1H, H-8), 6.23 (d, J = 7.1 Hz, 
2H, H-10). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.09 (C-2), 155.72 (C-6), 151.69 (C-12), 
140.66 (C-1), 120.12 (C-16), 63.53 (C-10). 
ESI-MS (m/z): [M-H]- calcd for C6H3F3N7O3-: 278.0 Da; found: 278.8 Da. 
Melting point: < 50 °C 
4-(((5-(3-(Benzyloxy)phenyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3- 
carboxylic acid 30 




4-(((5-(3-(benzyloxy)phenyl)-1H-tetrazol-1-yl)methyl)amino)-furazan-3-carboxylic acid 30 
was synthesized from 5-(3-(benzyloxy)phenyl)-1H-tetrazole 17 (378 mg, 1.5 mmol, 1.5 eq) 
according to Method 2 as a white solid. 
Yield: 108 mg (27%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 8.04 (t, J = 7.0 Hz, 1H, H-8), 7.69 – 7.14 (m, 9H, 
H-17, H-29, H-25, H-28, H-26, H-18, H-27, H-21, H-19), 6.10 (d, J = 7.0 Hz, 2H, H-10), 5.15 
(s, 2H, H-23). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 164.02 (C-6), 159.61 (C-20), 158.82 (C-2), 
155.29 (C-12), 136.81 (C-24), 130.60 (C-1), 128.50 (C-18), 128.47 (C-26, C-28), 127.89 
(C-27), 127.76 (C-16), 127.67 (C-25, C-29), 118.94 (C-17), 117.36 (C-19), 112.30 (C-21), 
69.37 (C-23), 62.55 (C-10). 
ESI-HRMS (m/z): [M+H]+ calcd for C18H16N7O4+: 394.1311 Da; found: 394.1264 Da. 
Melting point: 173 °C 
5-(Diethoxymethyl)-1H-tetrazole 31 
 
A solution of HN3 in chloroform was first prepared according to Method 3. 
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To the solution of HN3 (6 mL) was added 2,2-diethoxyacetonitrile (860 µL, 6 mmol, 1 eq) and 
pyridine (480 µL). The reaction solution was stirred at room temperature overnight. After 
completion of the reaction, the solvent was evaporated and saturated Na2CO3 solution (2 mL) 
was added. The resulting solution was washed with diethyl ether (3 × 3 mL). The aqueous 
phase was acidified with 4N HCl to pH = 2, followed by extraction with diethyl ether (6 × 3 
mL). The combined organic phases were concentrated and lyophilized to give product 31 as a 
white solid. 
Yield: 295 mg (28%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 5.98 (s, 1H, H-6), 3.63 (q, J = 7.1 Hz, 4H, H-9, 
H-10), 1.17 (t, J = 7.1 Hz, 6H, H-11, H-12). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 158.98 (C-1), 94.60 (C-6), 62.60 (C-9, C-10), 
15.49 (C-11, C-12). 
ESI-MS (m/z): [M+H]+ calcd for C6H13N4O2+: 173.1 Da; found: 173.3 Da. 
Melting point: 76 °C 
1-Benzyl-5-(diethoxymethyl)-1H-tetrazole 32 
 
To a solution of 5-(diethoxymethyl)-1H-tetrazole 31 (344 mg, 2 mmol, 1 eq) in DMF (5 mL) 
was added benzyl bromide (360 µL, 3 mmol, 1,5 eq) and cesium carbonate (800 mg, 2.4 
mmol, 1.2 eq). The reaction mixture was heated at 100 °C and stirred overnight. After 
completion of the reaction, the mixture was allowed to cool to room temperature and water 
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(10 mL) was added. The resulting solution was extracted with ethyl acetate (5 × 5 mL) and 
the combined organic phases were concentrated under reduced pressure. The product 
1-benzyl-5-(diethoxymethyl)-1H-tetrazole 32 and its isomer 2-benzyl-5-(diethoxymethyl)- 
2H-tetrazole 33 were separated by column chromatography (SiO2, n-hexane/ethyl acetate, 0% 
→ 20% ethyl acetate). After lyophilization, the product 32 was obtained as a colorless oil. 
Yield: 142 mg (27%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.48 – 7.31 (m, 5H, H-11, H-9, H-10, H-8, H-12), 
5.95 (s, 2H, H-6), 5.86 (s, 1H, H-13), 3.77 – 3.49 (m, 4H, H-16, H-17), 1.13 (t, J = 7.1 Hz, 6H, 
H-18, H-19). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 164.36 (C-1), 134.44 (C-7), 129.33 (C-8, C-12), 
129.09 (C-9, C-11), 128.84 (C-10), 95.13 (C-13), 61.88 (C-16, C-17), 56.49 (C-6), 15.39 
(C-18, C-19). 
ESI-MS (m/z): [M+H]+ calcd for C13H19N4O2+: 263.2 Da; found: 263.0 Da. 
2-Benzyl-5-(diethoxymethyl)-2H-tetrazole 33 
 
2-benzyl-5-(diethoxymethyl)-2H-tetrazole 33 was obtained simultaneously with 
1-benzyl-5-(diethoxymethyl)-1H-tetrazole 32 as a colorless oil. 
Yield: 210 mg (40%) 
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1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.45 – 7.26 (m, 5H, H-16, H-18, H-19, H-15, 
H-17), 6.06 (s, 1H, H-6), 5.74 (s, 2H, H-13), 3.71 (dd, J = 9.6, 7.1 Hz, 2H, H-9’, H-10’), 3.58 
(dd, J = 9.6, 7.0 Hz, 2H, H-9’’, H-10’’), 1.10 (t, J = 7.1 Hz, 6H, H-11, H-12). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 152.77 (C-1), 135.17 (C-14), 129.09 (C-16, 
C-18), 128.67 (C-15, C-19), 128.39 (C-17), 94.74 (C-6), 63.39 (C-9, C-10), 51.32 (C-13), 
15.18 (C-11, C-12). 
ESI-MS (m/z): [M+H]+ calcd for C13H19N4O2+: 263.2 Da; found: 263.0 Da. 
1-Benzyl-1H-tetrazole-5-carbaldehyde 34 
 
1-benzyl-5-(diethoxymethyl)-1H-tetrazole 32 (200 mg) was dissolved in 4N HCl (1 mL) and 
the solution was heated at 50 °C for 2.5 h. After complete conversion, the pH was adjusted to 
7 with saturated Na2CO3 solution. Extraction with ethyl acetate (3 × 3 mL) was then carried 
out. The combined organic phases were concentrated and lyophilized to give product 34 as a 
colorless oil. 
Yield: 120 mg (85%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 10.12 (s, 1H, H-13), 7.44 – 7.39 (m, 5H, H-9, 
H-11, H-10, H-8, H-12), 6.08 (s, 2H, H-6). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 182.96 (C-13), 162.75 (C-1), 134.00 (C-7), 
129.51 (C-8, C-12), 129.44 (C-10), 129.27 (C-9, C-11), 57.24 (C-6). 
ESI-MS (m/z): [M+H]+ calcd for C9H9N4O+: 189.1 Da; found: 189.0 Da. 





2-benzyl-5-(diethoxymethyl)-2H-tetrazole 33 (270 mg) was dissolved in 4N HCl (2 mL) and 
the solution was heated at 70 °C for 3 h. After complete conversion of the starting material, 
the pH was adjusted to 7 with saturated Na2CO3 solution. Extraction with ethyl acetate (3 × 3 
mL) was then carried out. The combined organic phases were concentrated and lyophilized to 
give product 35 as a white solid. 
Yield: 160 mg (84%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 9.56 (s, 1H, H-13), 7.46 – 7.29 (m, 5H, H-8, 
H-12, H-9, H-11, H-10), 5.73 (s, 2H, H-6). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 186.23 (C-13), 144.63 (C-1), 135.43 (C-7), 
129.46 (C-9, C-11), 129.03 (C-10), 128.73 (C-8, C-12), 51.34 (C-6). 
ESI-MS (m/z): [M+H]+ calcd for C9H9N4O+: 189.1 Da; found: 189.0 Da. 
Melting point: 59 °C 
1-Benzyl-5-(chloromethyl)-1H-tetrazole 36 
 
A solution of HN3 in toluene was first prepared according to Method 3. To a stirred 
suspension of N-benzyl-2-chloroacetamide (183 mg, 1 mmol, 1 eq) in toluene (5 mL) was 
added phosphorus pentachloride (229 mg, 1.1 mmol, 1.1 eq) under cooling. After 1.5 h of 
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stirring at room temperature, HN3 (3 mL) solution was added to the reaction mixture. The 
resulting mixture was heated to 80 °C and stirred overnight. After complete conversion of the 
starting material, toluene was removed under reduced pressure. To the residue was added 
water (10 mL) and extracted with ethyl acetate (3 × 10 mL). The combined organic phases 
were concentrated and lyophilized to give a pale yellow solid 36. 
Yield: 200 mg (96%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.44 – 7.38 (m, 2H, H-12, H-10), 7.37 – 7.27 (m, 
3H, H-11, H-13, H-9), 5.76 (s, 2H, H-7), 5.25 (s, 2H, H-1). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 152.94 (C-2), 134.68 (C-8), 129.38 (C-9, C-13), 
129.05 (C-11), 128.84 (C-10, C-12), 50.88 (C-7), 31.68 (C-1). 
ESI-MS (m/z): [M+H]+ calcd for C9H10ClN4+: 209.1 Da; found: 209.0 Da. 
Melting point: 66 °C 
N-Benzyl-2-(1,3-dioxoisoindolin-2-yl)acetamide 37 
 
To a stirred solution of 2-(1,3-dioxoisoindolin-2-yl)acetic acid (410 mg, 2 mmol, 1 eq) in 
dichloromethane (7 mL) was added oxalyl dichloride (253 µL, 3 mmol, 1.5 eq) and DMF (2 
drops) at room temperature. After 4 h, benzylamine (326 µL, 3 mmol, 1.5 eq) was added 
slowly into the reaction solution followed with addition of triethylamine (411 µL, 3 mmol, 1.5 
eq). After 30 min stirring, the reaction solution was washed with 2N HCl (1 × 5 mL) and 
evaporated under reduced pressure. The residue was washed with water and hexane. A white 
solid 37 was obtained after drying. 
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Yield: 567 mg (96%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 8.75 (t, J = 5.9 Hz, 1H, H-12), 7.95 – 7.90 (m, 2H, 
H-6, H-3), 7.90 – 7.85 (m, 2H, H-1, H-2), 7.37 – 7.29 (m, 2H, H-21, H-19), 7.29 – 7.21 (m, 
3H, H-20, H-18, H-22), 4.30 (d, J = 5.9 Hz, 2H, H-16), 4.27 (s, 2H, H-10). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 168.16 (C-7, C-9), 166.73 (C-11), 139.57 (C-17), 
135.11 (C-1, C-2), 132.40 (C-4, C-5), 128.88 (C-19, C-21), 127.72 (C-18, C-22), 127.43 
(C-20), 123.77 (C-3, C-6), 42.79 (C-10), 40.81 (C-16). 
ESI-MS (m/z): [M+H]+ calcd for C17H15N2O3+: 295.1 Da; found: 295.0 Da. 
Melting point: 217 °C 
2-((1-Benzyl-1H-tetrazol-5-yl)methyl)isoindoline-1,3-dione 38 
 
A solution of HN3 in toluene was first prepared according to Method 3. 
To a stirred suspension of N-benzyl-2-(1,3-dioxoisoindolin-2-yl)acetamide 37 (250 mg, 0.85 
mmol, 1 eq) in toluene (5 mL) was added phosphorus pentachloride (200 mg, 0.96 mmol, 1.1 
eq) under cooling. After 1.5 h of stirring at room temperature, HN3 (3 mL) solution was added 
to the reaction mixture. The resulting mixture was heated to 80 °C and stirred overnight. After 
complete conversion of the starting material, toluene was removed under reduced pressure. To 
the residue was added water (10 mL) and extracted with ethyl acetate (3 × 10 mL). The 
combined organic phases were concentrated and lyophilized to give a colorless oil 38. 
Yield: 213 mg (78%) 
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1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.92 – 7.82 (m, 4H, H-6, H-3, H-1, H-2), 7.34 – 
7.21 (m, 5H, H-23, H-21, H-22, H-20, H-24), 5.78 (s, 2H, H-18), 5.18 (s, 2H, H-10). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 167.54 (C-7, C-9), 152.01 (C-11), 135.36 (C-1, 
C-2), 134.65 (C-19), 131.87 (C-4, C-5), 129.40 (C-20, C-24), 128.81 (C-22), 128.00 (C-21, 
C-23), 124.00 (C-3, C-6), 50.70 (C-18), 31.47 (C-10). 
ESI-MS (m/z): [M+H]+ calcd for C17H14N5O2+: 320.1 Da; found: 320.3 Da. 
(1-Benzyl-1H-tetrazol-5-yl)methanamine 39 
 
To a stirred solution of 2-((1-benzyl-1H-tetrazol-5-yl)methyl)isoindoline-1,3-dione 38 (210 
mg, 0.66 mmol, 1 eq) in ethanol (10 mL) was added hydrazine monohydrate (131 µL, 2.6 
mmol, 4 eq). The resulting solution was heated to reflux. After 1.5 h, the solution was 
concentrated under reduced pressure. To the residue was added water (20 mL) and the 
precipitate formed was removed by filtration. The filtrate was extracted with dichloromethane 
(3 × 15 mL) and the combined organic extracts were washed with brine (2 × 20 mL), 
concentrated and lyophilized to afford product 39 as a colorless oil. 
Yield: 106 mg (85%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.57 – 7.11 (m, 7H, H-10, H-12, H-11, H-14, 
H-13, H-9), 5.72 (s, 2H, H-7), 4.01 (s, 2H, H-1). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 156.73 (C-2), 135.38 (C-8), 129.40 (C-9, C-13), 
128.84 (C-11), 128.56 (C-10, C-12), 50.40 (C-7), 35.17 (C-1). 
ESI-MS (m/z): [M+H]+ calcd for C9H12N5+: 190.1 Da; found: 190.3 Da. 
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4-((Cyanomethyl)amino)-furazan-3-carboxylic acid 40 
 
To a stirred suspension of 4-amino-furazan-3-carboxylic acid 1 (387 mg, 3 mmol, 1 eq) and 
sodium cyanide (587 mg, 9 mmol, 3 eq) in DMSO (9 mL) at room temperature was added 36% 
formaldehyde solution (462 µL). After 5 h, water was added and the pH was adjusted to 2 
with concentrated HCl. The mixture was extracted with ethyl acetate (6 × 30 mL). The 
combined organic phases were dried over Na2SO4, condensed under reduced pressure and 
purified by column chromatography (SiO2, n-hexane/ethyl acetate, 40% → 80% ethyl acetate). 
After lyophilization, the product 40 was obtained as a white solid. 
Yield: 340 mg (67%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.16 (t, J = 6.3 Hz, 1H, H-8), 4.28 (d, J = 6.3 Hz, 
2H, H-10). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.14 (C-6), 156.29 (C-2), 140.72 (C-1), 
117.71 (C-11), 32.84 (C-10). 
ESI-HRMS (m/z): [M-H]- calcd for C5H3N4O3-: 167.0205 Da; found: 167.0215 Da. 
Melting point: 81 °C 
4-(((1H-Tetrazol-5-yl)methyl)amino)-furazan-3-carboxylic acid 41 




To a stirred solution of 4-((cyanomethyl)amino)-furazan-3-carboxylic acid 40 (190 mg, 1.13 
mmol, 1 eq) in water (5 mL) and isopropyl alcohol (2.5 mL) was added sodium azide (147 
mg ,2.26 mmol, 2 eq) and zinc bromide (127 mg, 0.57 mmol, 0.5 eq). The reaction mixture 
was refluxed at 80 °C for 24 h. After cooling to room temperature, the solution was diluted 
with water (10 mL) acidified with concentrated HCl to pH = 2. The solution was extracted 
with ethyl acetate (3 × 20 mL). The combined organic phases were dried over Na2SO4. After 
removal of the solvent under reduced pressure, the product 41 was obtained as a white solid. 
Yield: 201 mg (84%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.19 (t, J = 6.1 Hz, 1H, H-8), 4.76 (d, J = 6.2 Hz, 
2H, H-10). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.48 (C-11, C-6), 156.91 (C-2), 140.69 (C-1), 
38.57 (C-10). 
ESI-HRMS (m/z): [M+H]+ calcd for C5H6N7O3+: 212.0532 Da; found: 212.0525 Da. 
Melting point: 176 °C 
Methyl 4-(((1H-tetrazol-5-yl)methyl)amino)-furazan-3-carboxylate 42 
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4-(((1H-tetrazol-5-yl)methyl)amino)-furazan-3-carboxylic 41 (180 mg, 0.85 mmol, 1 eq) acid 
was dissolved in methanol (3 mL) with catalytic H2SO4. The reaction mixture was stirred and 
heated to reflux. After 24 h, the solution was cooled to room temperature and water (15 mL) 
was added. The resulting solution was extracted with ethyl acetate (3 × 20 mL). The 
combined organic phases was evaporated under reduced pressure. After lyophilization, the 
product 42 was obtained as a white solid. 
Yield: 175 mg (91%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.32 (t, J = 6.1 Hz, 1H, H-8), 4.77 (d, J = 6.1 Hz, 
2H, H-10), 3.96 (s, 3H, H-16). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 159.13 (C-6), 156.91 (C-11), 156.66 (C-2), 
140.00 (C-1), 53.77 (C-16), 38.55 (C-10). 
ESI-MS (m/z): [M+H]+ calcd for C6H8N7O3+: 226.1 Da; found: 226.0 Da. 





























To a solution of methyl 4-(((1H-tetrazol-5-yl)methyl)amino)-furazan-3- carboxylate 42 (150 
mg, 0.67 mmol, 1 eq) in acetonitrile (6 mL) was added benzyl bromide (93 µL, 0.80 mmol, 
1.2 eq) and trimethylamine (93 µL, 0.67 mmol, 1 eq). The resulting solution was stirred at 
room temperature for 24 h. After completion of the reaction, the reaction mixture was 
evaporated under reduced pressure and the product 2,5-disubstituted tetrazole compound 43 
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and its isomer 1,5-disubstituted tetrazole compound 44 were separated by column 
chromatography (SiO2, n-hexane/ethyl acetate, 20% → 80% ethyl acetate). After 
lyophilization, the product was obtained as a white solid. 
Yield: 50 mg (24%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.43 – 7.23 (m, 6H, H-8, H-20, H-22, H-19, H-23, 
H-21), 5.91 (s, 2H, H-17), 4.68 (d, J = 6.2 Hz, 2H, H-10), 3.94 (s, 3H, H-16). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 164.28 (C-11), 159.17 (C-6), 156.60 (C-2), 
139.69 (C-18), 134.69 (C-19, C-23), 129.38 (C-20, C-22), 129.12 (C-21), 128.84 (C-1), 56.43 
(C-16), 53.73 (C-17), 39.69 (C-10). 
ESI-MS (m/z): [M+H]+ calcd for C13H14N7O3+: 316.1 Da; found: 316.0 Da. 




Methyl 4-(((1-benzyl-1H-tetrazol-5-yl)methyl)amino)-furazan-3-carboxylate 44 was obtained 
simultaneously with compound 43 a white solid. 
Yield: 43 mg (21%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.42 – 7.06 (m, 6H, H-8, H-20, H-22, H-19, H-23, 
H-21), 5.75 (s, 2H, H-17), 4.80 (d, J = 6.2 Hz, 2H, H-10), 3.92 (s, 3H, H-16). 
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13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 158.90 (C-6), 156.21 (C-2), 153.17 (C-11), 
139.42 (C-18), 135.04 (C-20, C-22), 129.17 (C-19, C-23), 128.65 (C-21), 127.92 (C-1), 53.67 
(C-16), 50.53 (C-17), 37.77 (C-10). 
ESI-MS (m/z): [M+H]+ calcd for C13H14N7O3+: 316.1 Da; found: 316.0 Da. 
Melting point: 102 °C 
4-(((2-Benzyl-2H-tetrazol-5-yl)methyl)amino)-furazan-3-carboxylic acid 45 
 
To a stirred solution of methyl 4-(((2-benzyl-2H-tetrazol-5-yl)methyl)amino)-1,2,5- 
oxadiazole-3-carboxylate 43 (200 mg, 0.63 mmol, 1 eq) in a mixture of methanol (1 ml) and 
water (1 ml) was added 1 N NaOH (1 mL). The mixture was stirred at room temperature for 
1.5 h. Upon completion of reaction, the solvent was evaporated under reduced pressure. The 
residue was dissolved in water (20 mL), acidified with concentrated HCl to pH = 2 and a 
white precipitate was formed as product 45.  
Yield: 150 mg (79%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.57 – 7.15 (m, 5H, H-19, H-21, H-18, H-22, 
H-20), 7.09 (t, J = 6.2 Hz, 1H, H-8), 5.90 (s, 2H, H-16), 4.67 (d, J = 6.1 Hz, 2H, H-10). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 164.34 (C-11), 160.52 (C-6), 156.86 (C-2), 
140.35 (C-17), 134.70 (C-1), 129.38 (C-18, C-22), 129.11 (C-19, C-21), 128.83 (C-20), 56.42 
(C-16), 39.69 (C-10). 
ESI-HRMS (m/z): [M+H]+ calcd for C12H12N7O3+: 302.1007 Da; found: 302.1001 Da. 
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Melting point: 183 °C 
4-(((1-Benzyl-1H-tetrazol-5-yl)methyl)amino)-furazan-3-carboxylic acid 46 
 
To a stirred solution of methyl 4-(((1-benzyl-1H-tetrazol-5-yl)methyl)amino)-1,2,5- 
oxadiazole-3-carboxylate 44 (200 mg, 0.63 mmol, 1 eq) in a mixture of methanol (1 ml) and 
water (1 ml) was added 1 N NaOH (1 mL). The mixture was stirred at room temperature for 
1.5 h. Upon completion of reaction, the solvent was evaporated under reduced pressure. The 
residue was dissolved in water (20 mL), acidified with concentrated HCl to pH = 2 and a 
white precipitate was formed as product 46. 
Yield: 144 mg (76%) 
1H-NMR (500 MHz, DMSO-d6): δ [ppm] = 7.59 – 6.83 (m, 6H, H-8, H-18, H-22, H-19, H-21, 
H-20), 5.75 (s, 2H, H-16), 4.79 (d, J = 5.9 Hz, 2H, H-10). 
13C-NMR (126 MHz, DMSO-d6): δ [ppm] = 160.31 (C-6), 156.56 (C-2), 153.23 (C-11), 
140.18 (C-17), 135.00 (C-1), 129.24 (C-19, C-21), 128.74 (C-18, C-22), 128.13 (C-20), 50.52 
(C-16), 37.79 (C-10). 
ESI-HRMS (m/z): [M+H]+ calcd for C12H12N7O3+: 302.1006 Da; found: 302.1001 Da. 
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